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ABSTRACT 
Tbx1, a gene encoding a T-box transcription factor, is required for embryonic 
development in humans and mice. Half dosage of this gene causes most of the features of 
the DiGeorge or Velocardiofacial syndrome phenotypes, including aortic arch and cardiac 
outflow tract abnormalities. Here we show that genetic ablation of Trp53 or pharmacological 
inhibition of its protein product p53 rescues almost completely aortic arch defects and 
significantly ameliorates outflow tract defects of Tbx1 mouse mutants. Trp53 deletion 
rescues the cell proliferation deficit in the second heart field of Tbx1 mutants. In addition, and 
surprisingly, Tbx1 and p53 proteins can be found on neighboring sites on chromatin, 
suggesting that they share a set of target genes. In a search for shared targets, we found 
that the expression of Gbx2, a gene that interacts with Tbx1 during development of the aortic 
arch arteries, is down regulated by Tbx1 heterozygosity and rescued by Trp53 
heterozygOSity. In addition, Tbx1 and p53 occupy the Gbx2 gene, indicating that both 
contribute to its regulation. 
Overall our data identify unexpected interactions between Tbx1 and Trp53 and 
provide a proof of principle that developmental defects associated with reduced dosage of 
Tbx1 can be rescued pharmacologically. 
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CHAPTER 1 - INTRODUCTION AND BACKGROUND 
1.1 Genetic basis of the D/George Syndrome 
The term "genomic disorders" refers to those diseases that are caused by chromosomal 
rearrangements involving large regions of one to several megabase pairs (Lupski 1998). 
Chromosomal rearrangements can result in interstitial or terminal deletions or duplications, 
as well as unbalanced translocations, and all of these consequences may subsequently 
result in imbalanced gene dosage. Each of these rearrangements occurs sporadically in the 
population and therefore represents the product of de novo mutations. Most of the 
rearrangements are associated with both congenital malformations and mental retardation. 
Therefore, genomic disorders have a large impact on human health. 
The 22q11 region serves as a model for genomic disorders because it is particularly 
susceptible to chromosomal rearrangements, leading to three different congenital 
malformation syndromes. 
In the late '60s, Angelo DiGeorge described a syndrome characterized by aberrant 
development of the thymus and parathyroid (DiGeorge AM, 1968). The phenotypic spectrum 
of DiGeorge syndrome (DGS) has since been extended to include many organs and clinical 
characteristics. including growth retardation. psychiatric disorders and congenital heart 
disease; the latter being the most dramatic feature and most common cause of death. 
The 22q11.2 deletion has been identified in the majority of patients with DiGeorge syndrome 
(de la Chapelle. Herva et al. 1981; Kelley. Zackai et al. 1982; Scambler. Carey et al. 1991; 
Driscoll. Budarf et al. 1992). Velocardiofacial syndrome (Driscoll. Spinner et al. 1992; 
Driscoll. Salvin et al. 1993) and Conotruncal Anomaly Face syndrome (Bum, Takao et al. 
1993; Matsuoka. Takao et al. 1994). Originally described as individual entities by a number 
of subspecialists who were concentrating on one particular area of interest. following the 
widespread use of fluorescence in situ hybridization (FISH). these syndromes are now 
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collectively referred to by their chromosomal etiology the 22q11.2 deletion syndrome 
(22q11.2DS) (McDonald-McGinn, Emanuel et al. 1996). The 22q11.2DS is the most common 
microdeletion syndrome with an estimated incidence of 1 in 4,000 live births. In most cases, 
the deletion occurs de novo, but in about 10% of cases it is inherited from a mildly affected 
parent (Scam bier 2000), thus behaving as an autosomal-dominant trait. 
22q11.2DS is caused by heterozygous deletions in the chromosome region 22q11.2. It has 
been proposed that deletion may result from aberrant homologous recombination between 
low copy repeat (LCR) sequences that flank the deleted region (Edelmann, Pandita et al. 
1999; Shaikh, Kurahashi et al. 2000). LCRs might confer instability to the region by mediating 
aberrant homologous recombination and unequal crossing over events during meiosis due to 
high sequence similarity between the repeat segments, thereby generating chromosomal 
rearrangements of a uniform and predictable size (Shaikh, Kurahashi et al. 2000). 
The majority of patients (85%) have a common 3 megabases (Mb) deletion encompassing 
30 genes, and -8% has an 1.5 Mb nested deletion encompassing 24 genes (Fig. 1) (Lindsay, 
Goldberg et al. 1995; Shaikh, Kurahashi et al. 2000). 22q11.2DS can be associated with a 
broad phenotype, but the most characteristic features are congenital heart disease and 
thymic and parathyroid aplasia or hypoplasia. This syndrome is characterized by neonatal 
hypocalcemia, which may present as tetany or seizures, due to hypoplasia of the parathyroid 
glands, and susceptibility to infection due to a deficit of T cells. The immune deficit is caused 
by hypoplasia or aplasia of the thymus gland. A variety of cardiac malformations are seen in 
particular affecting the outflow tract; these include tetralogy of Fallot, type B interrupted aortic 
arch, truncus arteriosus, right aortic arch and aberrant right subclavian artery. 
Other common findings are facial anomalies. In infancy, micrognathia may be present; the 
ears are typically low set and deficient in the vertical diameter with abnormal folding of the 
pinna; telecanthus with short palpebral fissures is seen; both upward and downward slanting 
eyes have been described; the philtrum is short and the mouth relatively small. 
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Short stature, renal anomalies, skeletal anomalies and variable mild to moderate learning 
difficulties are common. A variety of psychiatric disorders have been described in a small 
proportion of adult cases of velocardiofacial syndrome. These have included paranoid 
schizophrenia and major depressive illness. Clinical features seen more rarely include 
hypothyroidism, cleft lip, and deafness. 
Most features show variable expressivity and penetrance. In addition to having physical 
malformations, most affected children have learning disabilities and behavioral disorders 
(Swillen, Oevriendt et a/. 1999). Adults with this syndrome develop major psychiatric 
illnesses, including schizophrenia and bipolar disorder (Chow, Bassett et a/. 1994; Pulver, 
Nestadt et al. 1994; Papolos, Faedda et al. 1996; Murphy, Jones et a/. 1999; Shprintzen 
2000; Murphy and Owen 2001). 
The prognosis for 22q11.20S varies widely, depending largely on the nature and degree of 
involvement of different organs, and many adults live long and productive lives. 
The most common cause of mortality in 22q 11.20S is a congenital heart defect and the 
second most common is severe immune deficiency. Mortality is higher in infancy because of 
the severity of these 2 conditions. Infants with thymus aplasia present with severe 
immunodeficiency and typically die of sepsis, which usually results from bacterial or fungal 
infections. 
In a large European collaborative study, 558 patients with 22q11.20S were evaluated using 
a questionnaire (Ryan, Goodship, et a/. 1997). Eight percent of the patients died, with more 
than half of the deaths occurring within the first month of life and the majority happening 
within 6 months of birth. Of the patients who survived, 62% had only mild learning problems 
or were developmentally norma/. All but one of the deaths was attributable to congenital 
heart disease. 
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Figure 1: Human 22q11 deleted region. The 22q11 deleted region on human chromosome 
22, on which selected genes (green) and molecular markers (black) that have been used to 
characterize patient deletions are shown. Red blocks represent low-copy repeats (LCRs). 
AOU (blue) is a patient with OiGeorge syndrome and a balanced chromosomal translocation . 
The common 3 Mb typically deleted region (TOR), which is present in more than 85% of 
22q11 deleted patients and the 1.5 Mb deletion are shown (turquoise) (Lindsay 2001). 
1.2 Mapping causative genes 
Identifying the genes that underlie the pathogenesis of chromosome deletion and duplication 
syndromes is a challenge because the affected chromosomal segment can contain many 
genes. Creating chromosomal rearrangements that include or exclude given sets of genes in 
an experimental model is a way to resolve the genetics of these genomic disorders. This has 
been the strategy of several groups, whose research focuses on unravelling the molecular 
genetics of the 22q11 .20S. 
Several researchers have used the mouse as a model to study the 22q11 .20S, since there is 
a strong homology between a region on mouse chromosome 16 and the region on human 
chromosome 22 (Fig . 2) (Scambler 2000). Using chromosome-engineering strategies, three 
research groups generated deletions in mice that encompassed subsets of the genes 
deleted in patients with 22q11 .20S (Lindsay, Botta et al. 1999). 
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Figure 2: The mouse chromosome 16 region that is syntenic with 22q11.2. The gene 
content of the region deleted in 22q11.2DS patients is highly conserved in the mouse 
genome, although several ancestral rearrangements have led to changes in gene order 
between the two species. Mouse mutants have been reported for the genes that are marked 
with an asterisk. (a-d) Mouse chromosome 16 deletion mutants that have been made by 
different groups. Yellow indicates deleted or duplicated, and purple indicates non-deleted or 
non-duplicated, chromosome segments. The blue bar shows the extent of a transgene that 
rescues cardiovascular defects in Of1/+ mutant(Lindsay 2001). 
The first generated mouse deletion was named Of1 (Lindsay, Botta et al. 1999), which 
encompassed mouse homologues of 18 out of the 24 genes that are deleted in patients with 
the 1.5 Mb deletion (Fig. 2). Mice carrying one copy of the deleted chromosome (Of1/+) had 
cardiovascular defects similar to those seen in human patients (Fig. 3). Furthermore, the 
cardiovascular defects could be corrected in mice that were bred to carry the Of1 deletion on 
one chromosome 16, and a reciprocal duplication (Op1) on the other, which restored normal 
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gene dosage. This genetic-rescue experiment showed that a gene(s) within the Of1 region is 
involved in heart development and is haploinsufficient in these mutant mice. 
a 
Wild type 
'3 
T 
TbJI 1 . /- or Df11 + 
AS .. _~_~ 
T T 
Figure 3: Cardiovascular defects in mutant embryos. (a) At embryonic day (E) 10.5, 
Tbx1+1- embryos and 0'1/+ embryos have abnormally small or absent fourth aortic-arch 
arteries. In Tbx1-1- embryos, there is no development of the pharyngeal apparatus distal to 
arch two. As a result, arch arteries three to six do not form, and the aortic sac (AS) connects 
directly with the dorsal aorta (OA). (b) In near-term embryos (E 18.5), Tbx1 +1- embryos and 
Of1/+ embryos have abnormalities in the structures that derive from the fourth aortic-arch 
arteries, which are the root of the right common carotid (RCC) and a segment of the aortic 
arch. The resultant abnormalities include aberrant right subclavian artery (RSA), which 
originates from the aortic arch instead of from the RCC, and an interrupted aortic arch 
(asterisk). Tbx1-1- embryos have persistent truncus arteriosus (PTA), in which a single vessel 
exits the heart instead of the normal two, the aorta (AO) and pulmonary trunk (PT). Blue and 
red vessels indicate pulmonary and aortic arterial flow, respectively. Purple indicates that in 
the presence of the PTA abnormality, blood from both sides of the heart is mixed. Arrows 
indicate the direction of blood flow from the heart. (LCC, left common carotid ; LPA, left 
pulmonary artery; LSA, left subclavian artery; RPA, right pulmonary artery; T, trachea; TA, 
truncus arteriosus) (Lindsay 2001). 
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Two other mouse deletions were subsequently reported (Fig. 2) that partially overlapped with 
the Of1 deletion: the first deletion encompassed 7 genes (Of2) (Kimber, Hsieh et al. 1999), 
and the second encompassed 12 genes (Df3) (Puech, Saint-Jore et al. 2000). Mice that were 
heterozygous for either deletion had normal heart development, indicating that the gene 
responsible for the cardiovascular defects in Of1/+ mice lay in the interval between the genes 
Arvcf and Ufd11, which contains eight genes (Fig. 2). Within that interval, mice with null 
mutation in two genes, Comt (Gogos, Morgan et al. 1998) and Pnutl1 (Lindsay, Vitelli et al. 
2001), had been reported, but neither had cardiovascular defects. To ascertain which of the 
remaining six genes in the critical region was responsible for the cardiovascular phenotype, 
two of the groups used a combination of genetically engineered nested deletions and 
duplications, transgenesis and single-gene targeting (Lindsay, Vitelli et al. 2001; Merscher, 
Funke et al. 2001). Both groups identified a genomiC DNA fragment that contained four 
genes: Gnb 11, Tbx1, Gp 1 bb and Pnutl1, which corrected the cardiovascular defects when 
introduced into the Of1 deletion mice (Lindsay, Vitelli et al. 2001). This indicated that at least 
one of the genes present in this genomic region was responsible for the cardiovascular 
phenotype. 
To identify the gene responsible for the cardiovascular phenotype, both groups took a 
candidate-gene approach, selecting to knock out Tbx1 in the mouse. This gene is a member 
of the T -box family of genes, and was considered to be the strongest candidate because 
during embryonic development it is highly expressed in the pharyngeal apparatus (Chapman. 
Garvey et al. 1996) (Fig. 4). which gives rise to the structures that are most commonly 
affected in 22q11.20S. 
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Figure 4: Tbx1 expression in early mouse embryogenesis. Tbx1 expression shown by a 
lacZ reporter gene that has been inserted into the Tbx1 locus. (a) On embryonic day (E) 
10.5 , Tbx1 is expressed in the pharyngeal arches (pa), the pharyngeal pouches (pp) and in 
the otocyst (0), which will form the inner ear. (h, heart.) (b) At E10.5, Tbx1 is strongly 
expressed in the pharyngeal endoderm (green, light shade in Tbx1+1- indicates 50% 
reduction of gene dosage), which lines the developing pharynx (p). The fourth 
pharyngealarch artery (4) is small or absent in Tbx1 +1- and 0'1/+ embryos. 3, third 
pharyngeal-arch artery. (A, anterior; P, posterior; 0, dorsal; V, ventral) (Lindsay 2001). 
The finding of cardiovascular defects in Tbx1+1- mice that were identical to those found in 
0'1/+ mice (Fig. 3), provided compelling evidence that Tbx1 alone is responsible for that 
phenotype. The phenotype of Tbx1-null mice was remarkably reminiscent of severe forms of 
22q11.2DS (Jerome and Papaioannou 2001), indicating that human TBX1 might be involved 
in both cardiovascular and non-cardiovascular aspects of the 22q11 .2DS phenotype. 
TBX1 was confirmed to be the major genetic determinant of 22q11.2DS in 2003, when the 
screening of 10 patients with DGSNCFS without deletion, identified missense mutations in 
two patients with sporadic disease and one truncation mutation segregating in a family with 
the characteristic 22q11 .2DS phenotype (Yagi, 2003). The truncation mutation was shown to 
result in loss of function due to the deletion of a C-terminal nuclear localization signal of 
TBX1 (Stoller, 2005). A C-terminal truncating mutation was identified in another family with 
the DGSNCFS phenotype, but without the common deletion (Paylor, 2006). The third 
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missense mutation and the fifth overall mutation in TBX1 expanding the associated 
phenotype was found in a familial case of Shprintzen syndrome (Zweier, 2007), 
characterized by the typical facial gestalt of DGSNCFS. Thus, to date, only 5 TBX1 
mutations have been reported, suggesting that the mutation is very rare. 
1.3 Tbx1 and the T-box family 
Tbx1 encodes a member of an evolutionarily conserved T-box family of transcription factors, 
whose expression is precisely regulated during embryogenesis. Brachyury (n is the founder 
member of the T-box gene family (Smith J, 1997). In 1994, 80llag et al. (Bollag, Siegfried et 
al. 1994) showed the existence of a family of T-related genes in the mouse genome, which 
was named T-box gene family. Members ofthis family are expressed in, and are required for, 
the development of multiple cell types in diverse organisms. The family has 18 members in 
mammals that can be divided into five major phylogenetic subfamilies based on overall 
sequence similarity and gene structure (Minguillon and Logan, 2003). The Tbx1 subfamily 
includes Tbx10, Tbx15, Tbx18, Tbx20 and Tbx22. The defining feature of the T -box gene 
family is a conserved domain that was first uncovered in the sequence of the mouse T locus; 
this homology domain encodes a polypeptide region that was named the T-box (801lag, 
Siegfried et al. 1994). It is defined as the minimal region within the T-box protein that is both 
necessary and sufficient for sequence-specific DNA binding (Conlon, Fairclough et al. 2001; 
Papaloannou 2001). Despite the sequence variations within the T-box between family 
members, examination of downstream targets and binding-site selection experiments for a 
number of T -box proteins show that all members of the family so far examined bind to the 
DNA consensus sequence TCACACCT. T-box proteins have been demonstrated to function 
both as transcriptional activators and repressors. In all cases studied, the transcriptional 
regulation activity has been shown to require sequences located in the carboxy-terminal 
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portion of the protein (Conlon, Fairclough et al. 2001). Tbx1 has been shown to function as a 
transcriptional activator in several experimental systems. TBX1 is capable of activating an 
engineered CAT reporter construct with one copy of the typical palindromic Brachyury 
binding site in mammalian cells (Paylor, Glaser et al. 2006). Tbx1 was also found to be able 
to activate an Fgf10 promoter via a TbxS binding element in tissue culture (Xu, Morishima et 
al. 2004). Furthermore, Tbx1 has also been shown to function as a transcriptional repressor 
(Pane, Zhang et al. 2012). The T-box genes share two characteristics of interest to 
researchers studying cell specification and differentiation: they tend to be expressed in 
specific organs or cell types, especially during development, and they are generally required 
for the development of those tissues. These considerations, together with their DNA-binding 
and transcriptional activation/repression capacity, mean that T-box proteins are well placed 
to fulfill a wide array of important regulatory roles in development. This is supported by the 
observation that mutant alleles commonly give a phenotype even in heterozygotes (that is, 
they show haploinsufficiency), indicating that the level of a T-box protein is important for 
determining its function. 
1.4 Tbx1 expression pattern 
Tbx1 expression varies both spatially and temporally across tissues, and gene dosage 
studies in mice have shown that Tbx1 expression during embryogenesis requires precise 
regulation (Xu, Cerrato et al. 200S); expression analyses have shown dynamic Tbx1 
expression in tissues that form the pharyngeal apparatus (including pharyngeal endoderm, 
mesodermal core of pharyngeal arches, head mesenchyme, the second heart field, the 
otocyst and sclerotome), which gives rise to the heart and face (Chapman, Garvey et al. 
1996; Vitelli, Morlshima et al. 2002; Xu, Morishima et al. 2004). Tbx1 was not detected in the 
blastocyst, but in the 7.S dpc egg cylinder expression was observed in the embryonic 
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mesoderm, and in no other tissues (Chapman, Garvey et al. 1996). In the 8.0 dpc Tbx1 is 
expressed in the pharyngeal endoderm and in the mesodermal core of the 1 st pharyngeal 
arch. In the mid-gestation, Tbx1 expression revealed by both RNA in situ hybridization and a 
LacZ knock-in allele (Tbx1,acz) shows specific pattern in the pharyngeal region and otic 
vesicle. The strongest expression is observed in the endoderm lining the 3rd pouch and 3rd 
arch (Vitelli, Morishima et al. 2002). Expression in the pharyngeal region is both 
mesenchymal and epithelial: it is in the core mesenchyme of the 1 st, 2nd and 3rd pharyngeal 
arches, and in the epithelium of the 1 st, 2nd and 3rd pharyngeal pouches. Expression in the 
otic vesicle is predominantly in the caudal half, but includes both the epithelium and the 
surrounding mesenchyme. In 10.5 dpc embryos, when the pharynx has grown to include the 
4th arch, 4th pouch and 6th arch, Tbx1 in the endoderm is again expressed most strongly in 
the posterior segments. In addition to this anteroposterior gradient of expression, we 
observed higher expression towards the dorsolateral folds of the pharynx. At 11.5 dpc, 
endodermal expression persists almost exclusively in the 4th pouch. Hence Tbx1 is 
expressed following anterior-posterior and medial-to-Iateral gradients. These are also the 
directions of growth of the pharynx, suggesting that Tbx1 may be involved in the growth 
process (Vitelli, Morishima et al. 2002). By 12.5 dpc, expression is still evident in the otic 
vesicle epithelium. There is also expression in the mesenchyme surrounding the cochlear 
duct and the Eustachian tube epithelium. By 12.5 dpc, with organogenesis well underway, 
several additional sites of Tbx1 expression are evident. They are the myogenic core of the 
tongue, the incisor tooth buds, the mesenchyme surrounding Rathke's pouch and the 
branching lung epithelium (Chapman, Garvey et al. 1996). At pre-term stage, a Tbx1'acz allele 
reveals new expression domain in blood vessels of brain surface and parenchyma and this 
brain expression increases steadily from E17.5 to 12 weeks by real-time PCR (Paylor, Glaser 
et al. 2006). 
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1.5 The development of PAAs and their derivatives 
The mature aortic arch and great vessels derive from the embryonic pharyngeal arch arteries 
(PAAs) and the aortic sac. The PAAs are components of the pharyngeal apparatus, a 
vertebrate-specific structure comprising altemating bulges (arches) and indentations 
(pouches and clefts) that develops sequentially along the body axis in a head-to-tail direction. 
The pharyngeal arches are overlaid by surface ectoderm and lined by endoderm, which were 
referred to together as the pharyngeal epithelia. Between the epithelial layers of the 
pharyngeal apparatus there is mesenchyme of mesodermal origin that is later infiltrated by 
ectomesenchyme of neural crest origin. The endothelial cells of the PAAs are mesoderm ally 
derived and the surrounding tissue layers (pericytes and smooth muscle cells) develop from 
neural crest derived cells. The PAAs, which connect the aortic sac with the dorsal aortae, 
and which pass through the core of the arches, initially form as five pairs of symmetrical 
vessels. Beginning around embryonic day (E) 11.5 of mouse development, the caudal PAAs 
and the aortic sac remodel extensively to form the mature asymmetric aortic arch and great 
vessels. Proper remodeling of the PAAs into the aortic arch system is a complex process, 
requiring intercellular signaling events and correct spatiotemporal gene expression in 
multiple cell types. Migration and differentiation of neural crest-derived cells as well as 
growth and apoptosis of the developing vessels within a biomechanically active environment 
is a prerequisite of normal PAA transformation (Hutson and Kirby 2007; Snider, Olaopa et al. 
2007). 
In 12-somite embryos in the late part of the period E8.5-9, the pharyngeal arch artery system 
was not yet apparent, and the arterial trunk projecting from the endocardiac tube of the heart 
bifurcated into paired ventral aortae. The ventral aortae connected with the dorsal aortae 
through a loop (Fig. SA), which, together with the ventral aortae, is generally called the 1st 
pharyngeal arch artery. Until 15-somite stage, the ventral and dorsal aortae were still 
connected solely by the first PM and the 2nd PM was observed only as signs of sprouting 
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at the sides of the aortic sac and dorsal aorta (arrows in Fig. 5B). In the 16-somite embryo, 
the 2nd PM with a lumen, which was still thin, was established. By early in E9.5-10 embryo 
(21-23 somites), the 2nd PM had grown until its diameter approached that of the 1 st PM. 
Figure 5: Scanning electron microscopy (SEM) images of vascular casts of mouse 
embryos late in E8.5-E9 (12-somite stage, A) and early and late in E9-E9.5 (15-16-
somite stage, B). (A) Ventral view. The primitive intra-embryonic arterial system is seen. (B) 
Left side view. The sprouting indications of the 2nd PM can just be recognized (arrows) 
(Hiruma, Nakajima et al. 2002). paa: pharyngeal arch artery, va: ventral aorta, as: aortic sac, 
da: dorsal aorta, h: heart. Scale bar = 100 Ilm. 
The 3rd PM was first recognized at the 22-somite stage, but it was very thin and consisted 
of a network connecting the aortic sac to the dorsal aorta in the caudal part of the second 
pharyngeal pouch. In the middle part of E9.5-10 (24-26 somites), three paired PMs were 
clearly observed (Fig. 6A). The 1 st PM was thin, the 2nd PM was the thickest, and the 3rd 
PM gradually thickened as the stage of development increased. Late in E9.5-10 (27-29 
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somites), the 1 st PM had dwindled further, and it gave off numerous fine branches into the 
first pharyngeal pouch; the 3rd PM came to be thickest, and a very thin 4th PAA was 
forming just caudal to the 3rd (arrow in Fig. 6B). At E10 (31-34 somites), the 1st PAA was 
interrupted, and its distal part was transformed into the mandibular artery; this gave off many 
branches into the maxillary process. In addition, the 2nd PAA was now much thinner, 
becoming transformed into a thin capillary plexus. 
Figure 6: SEM images of vascular casts of mouse embryos in the middle (25-somite 
stage, A) and late (27-somite stage, B) parts of E9.5-E10. (A) Three PAAs (I, ", "I) are 
seen, of which the 2nd is the thickest. (B) The cephalic vascular system is well developed. 
The primordial of the 4th PM are present between the aortic sac and dorsal aorta (arrows) 
(Hiruma, Nakajima et al. 2002). pic: primitive internal carotid artery, va: ventral aorta, as: 
aortic sac, da: dorsal aorta. Scale bar = 250 f.lm. 
The 3rd PAA was the thickest, the 4th PAA was becoming thicker as the stage advanced 
from 32 to 34 somite stage (Fig. 7 A,B), and the very thin 6th PAA appeared, at a position 
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cadal to the 4th PM, connected the aortic sac to the dorsal aorta (Fig. 7C). The primordium 
of the pulmonary artery was first observed at this time, and in the 32- and 34-somite embryos 
it arose from the proximal part of the 6th PM and run straight in the caudal direction, parallel 
to the dorsal aorta (Fig. 7C). At E1 0.5 and E11, the mandibular artery had grown in size and 
gave off many branches to the jaw region; at this time, the 2nd PAA was interrupted and its 
distal part was transformed into the very thin hyoid artery. The proximal part, on the other 
hand, fused with the proximal part of the 1 st PM to form the primordium of the external 
carotid artery. 
Figure 7: SEM images of vascular casts of mouse embryos at E10 (32-somite stage, A-
B; 34-somite stage, C). All show right side view. (A) The interrupted line (top right) indicates 
the posterior part of the cranial division of the circle of Willis , which was broken during 
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preparation of the cast. (B) The remnants of the ventral aorta and the proximal portion of the 
1st PM (arrow) as well as the ventral primordial of the 6th PAA (arrowheads) can be 
discriminated. (C) The arrow pOints to the proximal portion of the 2nd PAA, and the 
arrowhead pOints to its distal portion. (Hiruma, Nakajima et al. 2002). as: aortic sac, h: heart, 
pa: pulmonary artery, da: dorsal aorta, psc: primitive subclavian artery. Scale bar in A = 500 
.... m; B-C = 250 11m 
At this stage, the 3rd, the 4th and the 6th PAAs were all well developed, and of almost equal 
thickness, and they formed connections between the aortic sac and the dorsal aorta (Fig. 8). 
Until E11, the pharyngeal arch artery system was bilaterally symmetrical. From E11 to E11.5, 
the portion between the basal parts of the 3rd, the 4th and the 6th PAA became elongated, 
and the vascular organization around the aortic sac changed (Fig. 9A). 
At E11.5, the aortic sac could be seen to be T-shaped, with right and left horns, and its 
proximal part was divided into the aortic trunk and pulmonary trunk (Fig. 9B). The pharyngeal 
arch artery system became asymmetrical at this stage. The dorsal aorta was small in 
diameter between the 3rd and the 4th PAAs; this is commonly called the carotid duct (arrow 
In Fig. 9C). 
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Figure 8: SEM images of vascular casts of mouse embryo at E1 1. Left side view. The 
hyoid artery, which was broken during preparation of the cast, remains only at its origin . The 
pulmonary artery branches from the mid-point of the 6th PM, and the primitive subclavian 
artery originates from the single dorsal aorta (Hiruma, Nakajima et al. 2002). pic: primitive 
internal carotid artery, ha: hyoid artery, as : aortic sac, h: heart, pa : pulmonary artery, da: 
dorsal aorta. Scale bar 500 flm . 
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Figure 9: SEM images of the vascular casts of mouse embryos at E1 1.S (A) and E12 (B, 
C). (A) Left side view. Origin of the 4th PM from the aortic sac is separated from that of the 
6th PM. The pulmonary arteries originate from the proximal part of the 6th PM (compare 
with Fig . SA). The primitive subclavian artery is given off from the boundary between the 
paired and single portion of the dorsal aorta. (B) Ventral view. The proximal portion of the 
aortic sac is divided into the aortic trunk and the pulmonary trunk. The primitive subclavian 
artery branches from the paired dorsal aorta . (C) Left side view. A vessel (arrowheads) is 
seen connecting the mandibular artery and hyoid artery. The carotid duct (arrow) is indicated. 
as: aortic sac, pa: pulmonary artery, da: dorsal aorta , psc: primitive subclavian artery, pec: 
primitive external carotid artery, at: aortic trunk, pt: pulmonary trunk, cd : carotid duct (Hiruma, 
Nakajima et al. 2002). Scale bar = 500 f.lm. 
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At E13, the 3rd PAA had become both the common carotid artery (CCA) and the proximal 
part of the internal carotid artery (ICA), since the carotid duct had disappeared (Fig. 10A). By 
then, the right dorsal aorta, which had been situated between the right subclavian artery 
(RSA) and the left dorsal aorta, had completely disappeared. As a result, the aortic-arch 
system had become bilaterally asymmetrical, and almost the same as in the adult (Fig. 
10B,C): that is to say, the right horn of the T-shaped aortic sac was transformed into the so 
called "innominate" artery or right brachiocephalic artery, while the left horn together with the 
left 4th PAA comprise the definitive aortic arch (AA). The right 4th PAA formed the proximal 
part of the subclavian artery, and the left became a distal division of the aortic arch. The left 
6th PAA persisted as the arterial duct between the pulmonary artery and the aortic sac. 
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Figure 10: SEM images of vascular casts of mouse embryos at E12.S (A) and E13 (B,C). 
(A) Ventral view. The right dorsal aorta is slender compared to the left. (8) Ventral view. The 
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particularly thin portion of the right dorsal aorta seen in A (arrow) has disappeared. (C) Left 
side view. The aortic arch system is quite similar to that seem in the adult (Hiruma, Nakajima 
et al. 2002). pic: primitive internal carotid artery, pec: primitive external carotid artery, as: 
aortic sac, at: aortic trunk, pt: pulmonary trunk, pa: pulmonary artery, da: dorsal aorta, psc: 
primitive subclavian artery, ic: definitive internal carotid artery, ec: definitive external carotid 
artery, cc: common carotid artery, bc: brachiocephalic artery, aa: definitive aortic arch, sc: 
definitive subclavian artery, a: definitive aorta, ad: arterial duct. Scale bar = 500 ~m. 
1.6 The role of Tbx1 gene during PAAs development 
The main cause of death in 22q11.2DS patients is congenital heart defects (CHDs), which 
affects the following tissues: the cardiac outflow tract (OFT; resulting in Tetralogy of Fallot 
and persistent truncus arteriosus); the fourth pharyngeal arch artery (PAA; resulting in 
interrupted aortic arch type B, IAA-B); and the right subcavian artery (resulting in aberrant 
origin of the right subcavian artery, ARSA) (McDonald-McGinn and Sullivan 2011). Moreover, 
most 22q11.2DS phenotypes, including CHDs, are caused by defects in development of the 
pharyngeal apparatus during early embryogenesis, and Tbx1 is a gene required for the 
development of this apparatus. 
The primary embryological defect underlying most of the cardiovascular abnormalities 
observed in Tbx1+1- embryos is defective development of the fourth pharyngeal arch arteries 
(PAAs) (Lindsay et al. 2001). Instead, Tbx1"'- mutants revealed severe disruption of the PAA 
system. In these embryos the third, fourth and sixth PAAs are absent and the dorsal aortae 
connected directly with the aortic sac, suggesting a severe developmental impairment of the 
pharyngeal arches. Thus Tbx1 is a dosage-sensitive gene, which when haploid results in 
fourth PM abnormalities and loss of function of Tbx11eads to disruption of PMs 3-6. Great 
artery defects Involving third and sixth PM derivatives are almost never seen in 22q11.2DS 
patients, suggesting that the haploinsufficiency models reflect more closely the aortic arch 
defects than do the homoxygous mutations. 
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In order to understand the mechanism by which Tbx1 dosage reduction affects fourth PAA 
development, it is important to determine where Tbx1 is required for this function. However, 
Tbx1 is expressed in many tissues that could contribute to fourth PM development. So it 
has been considered the Cre-driver strategy to be an effective way to address systematically 
the tissue requirement for Tbx1 in fourth PAA development. 
In mice, Tbx1 is required for fourth PAA formation and growth. 100% of Tbx1+1- embryos 
have hypoplastic fourth PAAs at E10.5, whereas, at term, 30-50% have fourth PAA-derived 
cardiovascular defects (specifically, IAA-B, RAA and AR5A), according to whether the left, 
right, or both fourth PAAs are affected (Lindsay and Baldini 2001). The penetrance of these 
defects in E10.5 and term embryos varies with genetic background (Zhang, Cerrato et al. 
2005). When the fourth PAA forms at around E9.75, Tbx1 is most highly expressed in the 
endoderm of the fourth arch and pouch. However, Tbx1 is expressed in many tissues 
potentially involved in the development of these arteries. 
To understand the developmental and genetic mechanisms governing the formation, growth 
and remodeling of the fourth PAAs, it is necessary to understand the role of the individual 
tissues. This can be approached using tissue-specific, gene-dosage reduction. To this end, a 
panel of Cre drivers that induce recombination in different tissues of the pharyngeal 
apparatus have been used to delete one copy of the Tbx1 gene. Results clearly indicate that 
the critical tissue for early fourth PAA development is the pharyngeal epithelia (Zhang, 
Cerrato et al. 2005). 
Tbx1 expression in the pharyngeal region was first seen at embryonic stage E8 in the 
surface ectoderm overlying the pharynx, in the pharyngeal endoderm and mesoderm (Fig. 11 
A,A'), and in the head mesenchyme. At E9, expression in the surface ectoderm extended 
over the presumptive caudal arches (Fig. 11 B,B'), whereas after E9.5, ectodermal 
expression was no longer detectable. Thus, Tbx1 expression in surface ectoderm precedes 
the formation of the fourth PAA at E9.75, suggesting that it may contribute to this process. 
Hence, both endoderm and ectoderm express Tbx1 in a region relevant to fourth PAA 
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formation . FgfB is also expressed in surface ectoderm at E9 and its expression in that tissue 
is required for fourth PAA development (Macatee, Hammond et al. 2003). Thus , it is possible 
that the reported genetic interaction between Tbx1 and FgfB (Vitell i, Taddei et al. 2002) 
operates through transcriptional regulation of the FgfB gene by Tbx1 in ectoderm . FgfB 
expression has been analyzed in Tbxrl- embryos between E9 and E10 and found it to be 
robustly expressed in surface ectoderm, although it was not expressed in the pharyngeal 
endoderm of these mutants . Thus, it is unlikely that Tbx1 regulates FgfB expression in 
pharyngeal ectoderm to PAAs development. 
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Figure 11: Tbx1 expression in the pharyngeal region. (A,A') X-gal staining pattern 
generated by a Tbx1 - lacZ knock-in allele (Tbx1 +1- ) at E8 (A), and in a transverse section 
through the pharynx of the same embryo (A'). 0 , dorsal ; V, ventral ; da, dorsal aorta ; se, 
surface ectoderm; pe , pharyngeal endoderm; pm, pharyngeal mesoderm; p, pharynx; h, 
heart. (8 ,8 ') Tbx1 expression in surface ectoderm overlying the presumptive caudal arches 
(arrowheads) at E9. (From Zhang Z. et aI. , 2005). A, anterior; P, posterior; II , III , second and 
th ird pharyngeal arch . 
In order to achieve recombination in pharyngeal mesoderm , another tissue in which Tbx1 is 
expressed by E8, a Mesp1 cre driver was used . Mesp1 cre induces recombination in 
mesoderm-derived tissues (Saga, Hata et al. 1996), but rigorously spares pharyngeal 
epithelia. In gastrulating embryos , Mesp1 is expressed by all mesodermal cells as they exit 
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the primitive streak between E6.5 and E7. As a result, Mesp1cre induces extensive 
recombination in a sub-population of mesoderm-derived tissues that include core arch 
mesoderm, pharyngeal mesoderm and vascular endothelium. Mesp1creI+ mutants were bread 
with Tbx1 f1oxlflox mutants and none of the embryos tested had fourth PAA defects, suggesting 
that the role of Tbx1 in fourth PAA development is not mediated by mesodermal expression 
(Zhang, Cerrato et al. 2005). 
Foxg1cre induces recombination in pharyngeal epithelia and in pharyngeal mesoderm, 
including the core arch mesoderm and second heart field. Foxg1cre1+ mutants were bread with 
Tbx1 f1oxlfloX mutants and results shown that the forty-two percent of Foxg1Cre conditional 
mutant embryos had hypoplasia of one or both fourth PAAs. Thus, Tbx1 gene-dosage 
reduction in Foxg1Cre-expressing cells, or daughter cells, is sufficient to cause fourth PM 
hypoplasia. The reduced penetrance of the fourth PAA phenotype may be do to the late 
activation (E8.5) of Cre-induced recombination of the Tbx1-floxed allele in some cells. 
To dissect further the tissue requirement of Tbx1 in fourth PM development a transgenic 
Fgf15Cre driver line that is specific for pharyngeal ectoderm and endoderm was used 
(Zhang, Cerrato et al. 2005). As no recombination was seen in the core arch mesoderm or 
arch mesenchyme, it has been concluded that recombination is epithelial specific. 
TgFgf1SC'-; Tbx1f/ox1+ conditional mutants had hypoplasia of one or both fourth PMs, 
indicating that Tbx1 dosage reduction In pharyngeal epithelia is sufficient to cause fourth 
PAA hypoplasia (Zhang, Cerrato et al. 2005). 
To map over time the role of Tbx1 gene in the development of pharyngeal derivatives and 
cardiovascular system, a time-course deletion on Tbx1 during embryogenesis was used. 
Results shown distinct time windows in which Tbx1 is required for different organs and 
structures. A drug-Induced Cre-mediated recombination of a Tbx1 conditional allele (Tbx1 f1ox), 
in which the exon 5, encoding part of the T -box domain, is flanked by LoxP sites (Xu, 
Morishima et al. 2004), was used. Cre-induced recombination of this allele generates the 
allele Tbx1·E5, which Is functionally nUll. To drive ere recombinase expression, a transgenic 
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mouse line (Tg-CAGG-CreER™) expressing ubiquitously a tamoxifen-inducible CreER™ 
protein (Hayashi and McMahon 2002) was used. Tg-CAGG-CreER™; Tbx1"ox/+ embryos 
exposed to tamoxifen at E7.5 demonstrated that heterozygous deletion of Tbx1 at this time 
point causes fourth PAAs defects. Exposure to tamoxifen at E8.5 of embryos with the same 
genotype results in normal or only mildly hypoplastic fourth PAA (Xu, Cerrato et al. 2005). 
Thus, the fourth PAA haploinsufficiency phenotype is due to an early requirement for Tbx1 
that precedes the morphological appearance of the arteries, which occurs after E9.5. 
Retinoic acid (RA), the active derivative of vitamin A (retinol), is a modifier of the PAA 
phenotype of Tbx1 mutants. In the developing PAs of the chick embryo, both the application 
of exogenous RA and reduction of RA levels repress Tbx1 gene expression (Roberts, Ivins et 
a!. 2005). 
RA acts as a ligand for nuclear receptors (RARs), which exist as three distinct Isotypes 
(RARa, -p, -y) and bind as heterodimers with retinoid X receptors to regulatory DNA 
sequences known as RA responsive elements (RAREs). Two enzymatic reactions convert 
retinol into RA. The retlnaldehyde (Ral) to RA conversion can be carried out by three 
members of the aldheyde dehydrogenase family, the retinaldehyde dehydrogenases 
(RALDH) 1, 2 and 3 (Mic, Molotkov et al. 2000). Among these, RALDH2 is expressed from 
gastrulation onward. Homozygous disruption of the mouse Raldh2 gene is early (around 
E10.5) embryonic lethal, because of defects in heart morphogenesis (Niederreither, Vermot 
et al. 2001), whereas RA-supplemented RaldhT- embryos display OFT defects and impaired 
development of posterior (3rd to 6th) PAAs. Consistent with these findings, Raldh2-null mice 
were found to exhibit DGS-like aortic arch defects (Vermot, Niederreither et al. 2003). Tbx1 
has also been implicated in the repression of RA signaling in experiments involving the 
down-regulation of Raldh2 (Ryckebusch, Bertrand et al. 2010). Interestingly, in Tbx1+/' mice 
with decreased RA levels, the penetrance of fourth PAA defects was reduced (Ryckebusch, 
Bertrand et al. 2010). Thus, it appears that a precise balance between Tbx1 expression and 
RA signaling is crucial for PAA development. 
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Chromatin modifiers also contribute to Tbx1 regulation during PAA development. A genetic 
interaction has been found between Tbx1 and the gene encoding the chromatin remodeling 
protein chromodomain helicase DNA-binding protein 7 (Chd7), which is mutated in CHARGE 
syndrome, that is a recognizable (genetic) pattern of birth defects which occurs in about one 
in every 9-10,000 births worldwide. It is an extremely complex syndrome, involving extensive 
medical and physical difficulties that differ from child to child. Babies with CHARGE 
syndrome are often born with life-threatening birth defects, including complex heart defects. 
Tbx1 and Chd7 are both required in the pharyngeal ectoderm for the growth and remodeling 
of the fourth PAAs. Both Tbx1 and Chd7 act cell-non-autonomously in this context, signaling 
to the mesenchymal cells that populate the PAs (Randall, McCue et al. 2009). 
Neuroepithelium-derived cardiac neural crest cells (cNCCs) are needed for proper septation 
of the OFT into the aorta and pulmonary trunk. cNCCs migrate through the PAs and 
differentiate into the vascular smooth muscle (VSM) layer through which the PAA pass 
(Hutson and Kirby 2007). Various signaling pathways play roles in the migration, proliferation 
and differentiation of these cells. Although, Tbx1 is not expressed in these cNCCs, it 
regulates their migration in a non-cell-autonomous manner, probably by activating 
expression of the homeobox-containlng gene Gbx2 in the pharyngeal surface epithelium 
(Calmont, Ivins et at 2009). Gbx2 encodes a homeobox trancription factor important for both 
development of the fourth PAA and proper cNCC migration into the PAs; cNCC patterning 
defects In mouse embryos lacking this gene lead to aortic arch defects such as IAA-B and 
also cardiac OFT defects, Including double outlet right ventricle (DORV) and overriding aorta 
(Byrd and Meyers 2005). 
34 
1.7 The development of the cardiac OFT 
The cardiac OFT is a structure of the arterial pole of the heart connecting the embryonic 
ventricles with the aortic sac. The OFT forms during heart looping from cardiac progenitor 
cells in pharyngeal mesoderm. At its maximal extension the OFT is a torsioned myocardial 
cylinder lined with endocardial cells; then, it is subsequently remodeled, concomitant with 
ventricular septation, during which process the OFT wall rotates and divides to generate the 
base of the ascending aorta and pulmonary trunk. Since the 1970s, studies revealed that 
cardiac growth occurs by addition of cells lying outside the early heart (de la Cruz, Sanchez 
Gomez et al. 1977). About ten years ago, a population of cardiac progenitor cells was 
identified in pharyngeal mesoderm that give rise to a major part of the heart. These 
multipotent progenitor cells, termed the second heart field (SHF), contribute progressively to 
the poles of the elongated heart tube during looping morphogenesis, giving rise to 
myocardium, smooth muscle, and endothelial cells. SHF cells originate in medial splanchnic 
mesoderm in the anterior region of the embryo, adjacent to pharyngeal endoderm (Fig. 12). 
Immediately contiguous lateral splanchnic mesoderm gives rise to the cardiac crescent and 
early heart tube (from Schoenwolf, Bleyl et at, 2009). The SHF is also patterned along the 
anterior-posterior embryonic axis. Anterior-SHF cells give rise to the right ventricle and OFT 
at the arterial pole, while the posterior component of the SHF contributes to atrial, atrial 
septal, and venous pole myocardium. The linear heart tube is thought to give rise 
predominantly to the left ventricle (Buckingham, Meilhac et at 2005). 
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Figure 12: Topography of the second heart field. (A) Cartoons showing the stages of 
mouse heart development during which second heart field progenitors are added to the 
heart. From left to right: embryonic day (E) 7.5 (cardiac crescent, ventral view), E8.5 (early 
heart tube, ventral view), E9.S (looped heart, left lateral view), and E 10.5 (ventral view) . 
Second heart heart field progenitor cells and their contribution to the heart are shown in dark 
blue and the early heart tube giving rise to the left ventricle in pink. Anterior (A) posterior (P) 
and medial (M) lateral (L) embryonic axes are indicated . (8) Schematized histological 
sections showing the location of second heart field cells and their myocardial derivatives 
(dark blue) at the stages shown in (A) relative to pharyngeal endoderm (yellow), myocytes 
derived from the early heart tube (pink), and neural crest-derived mesenchyme (orange). The 
first three panels show transverse sections at the levels indicated by the dotted lines in (A). 
The right hand panel shows a mid-saggital E9.S section . Dorsal (0) ventral (V) and medial 
(M) lateral (L) embryonic axes are indicated (from Kelly, RG 2012). CC, cardiac crescent; 
SHF, second heart field; HF, head fold; HT, heart tube , AP , arterial pole; VP , venous pole; 
OFT, outflow tract; LV, left ventricle ; LA, left atrium; RV, right ventricle ; RA, right atrium; A-
SHF, anterior component of the second heart field ; P-SHF, posterior component of the 
second heart field ; NT, neural tube; PH, pharynx; PC, pericardial cavity; OM , dorsal 
mesocardium; EN , enodcardium; Me, myocardium. 
The SHF cells differ from cells giving rise to the linear heart tube by two defining properties : 
continued prOliferation and differentiation delay (Rochais, Mesbah et al. 2009). These 
properties allow the progressive increase of SHF cells during heart tube elongation and are 
controlled by the dynamic pharyngeal signaling environment and the distinct pharyngeal 
mesodermal transcriptional program of the SHF. Fgf10 was identified as the first molecular 
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marker of the SHF (Kelly, Brown et al. 2001). SHF cells are also characterized by expression 
of genes encoding FgfB and the transcription factors 1s11 , Tbx1, Prdm1, and Six1 (reviewed 
in (Buckingham, Meilhac et al. 2005). Expression of these genes is downregulated upon 
differentiation, and regulators of cardiac specification, such as Nkx2.5, Gata4, and Mef2c, 
are activated as progenitor cells approach the heart tube (Waldo, Kumiski et al. 2001). The 
properties of continued proliferation and differentiation delay that define cardiac progenitor 
cells in the SHF are regulated by a complex network of intercellular signals that collectively 
describe the niche of the SHF in the caudal pharyngeal region. These signals both regulate 
and are regulated by transcription factors in pharyngeal mesoderm and adjacent cell types, 
including pharyngeal epithelia and neural crest-derived cells, as well as autocrine signals 
from pharyngeal mesoderm itself (Fig. 13) (Vincent and Buckingham 2010; Rochais, Mesbah 
et al. 2009). Other signals include bone morphogenetic protein (BMP), fibroblast growth 
factor (FGF), and canonical and noncanonical Wnt signaling (Evans, Yelon et al. 2010). 
These signals induce Mesp1 positive mesodermal progenitor cells to activate cardiac 
transcription factors, including 1s11 , Tbx5, Nkx2.5, Baf60e, and Gata4 that combinatorially 
drive cardiomyogenesis (van Weerd, Koshiba-Takeuchi et al. 2011; Bruneau, Nemer et al. 
2001). As the cardiac crescent and linear heart tube form, SHF cells in medial splanchnic 
mesoderm remain in contact with pharyngeal endoderm and their continued proliferation and 
delayed differentiation is regulated by canonical Wnt, FGF, and Hedgehog (Hh) signaling 
pathways (Fig. 13). So, pro-proliferation and pro-differentiation signaling appear to identify 
core antagonistic signaling pathways regulating progressive addition of SHF cells to the heart 
tube (Hutson, Zeng et al. 2010). The balance between these two pathways is influenced by 
neural crest cell invasion of the caudal pharyngeal region that plays a critical role in braking 
the proliferative effect of FGF signaling on SHF cells, in addition to a direct later role in OFT 
septation (Hutson, Zhang et al. 2006). 
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Figure 13: The regulation of second heart field development. (A) Cartoon showing zones 
of Wnt, fibroblast growth factor (FGF), Hedgehog (Hh), and bone morphogenetic protein 
(8MP) signaling at the arterial pole of the mouse heart. LV, left ventricle; RV, right ventricle; 
OFT, outflow tract; SHF, second heart field; NC, neural crest-derived cells . (8) Schema 
showing the network of major signaling pathways and regulatory genes impacting on 
progressive second heart field development during the transition from proliferating progenitor 
cell (top) to differentiated cardiomyocyte (bottom). Note the central position of Isl1 and Tbx1 
in regulating the proliferative progenitor cell state (top), the pivotal position of FGF/8MP 
antagonism in controlling the balance between proliferation and differentiation (middle), and 
the activation of the cardiomyogenic program by a network of interacting transcription factors 
(bottom). Gray lines, direct protein interactions; dotted lines, microRNA silencing (from Kelly , 
RG 2012). 
Transcription factors such as Is11 and Tbx1 play central roles in integrating the output of 
different signaling pathways during SHF development (Fig. 13B). Is11 is required for 
development beyond the linear heart tube stage and regulates signal ing pathways ligand and 
receptor gene expression in the pharyngeal region (Cai, Liang et al. 2003). Recent data from 
ES cell studies implicates Is11, together with Mesp1, in driving early cardiac specification 
(Bondue, Tannler et al. 2011). A growing number of additional transcription factors from 
diverse families, including forkhead, homeobox, T-box, Gata, Zinc-finger, and bHLH factors , 
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have been found to play important roles in SHF development and single and compound 
mutations in these genes impact on SHF development. Foxc1 and Foxc2 are required for 
arterial pole development and have been found, together with Foxa2, to transactivate Tbx1 
regulatory elements (Zhang and Baldini 2010). Foxc1 and Foxc2, together with Foxf1 and 
Gata4, also regulate /s/1 through a downstream enhancer (Kang, Nathan et al. 2009). Mef2c 
expression In the anterior-SHF is regulated by Isl1 and Gata4 as well as by Tbx20 (Dodou, 
Verzi et al. 2004). Finally, the homeodomain transcription factor Six1 and its coactivator Eya1 
are required for proliferation within the SHF and survival of adjacent tissues including 
pharyngeal epithelia and neural crest-derived mesenchyme. Promoter analysis and genetic 
interaction studies, position SiX/Eya transcriptional complex downstream of Tbx1 and directly 
upstream of FgfB expresson (Guo, Sun et al. 2011). 
Direct or indirect perturbation of SHF development results in congenital heart defects. Loss 
of function of /s/1 or earty ablation of key regulatory genes such as FgfB results in severe 
heart tube elongation defects and midgestation lethality (Cai, Liang et al. 2003; Park, 
Watanabe et al. 2008). Milder defects in heart tube elongation results in alignment defects 
and failure to separate systemic and pulmonary circulations at birth, corresponding to a 
variety of common congenital heart anomalies seen in human patients. These include 
conotruncal defects resulting from OFT hypoplasia and failure of ascending aorta to make 
the right connection with the left ventricle, such as ventricular septal defects, common arterial 
trunk, tetralogy of Fallot, and double outlet right ventricle. In the mouse, hypomorphic alleles 
of genes required for normal SHF development, such as Tbx1, can results in a similar 
spectrum of conotruncal defects (Zhang and Baldini 2008). However, specific subpopulations 
of SHF cells contributing to the terminal stages of SHF development appear to be particularty 
relevant with respect to the etiology of common congenital heart defects. ere-labeling 
experiments have shown that Tbx1 is expressed in a subpopulation of SHF cells giving rise 
to the Inferior and lateral wall of the midgestation OFT and later to myocardium at the base of 
the pulmonary trunk (Huynh, Chen et al. 2007). Underdevelopment of the myocardium at the 
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base of the pulmonary trunk is considered to be the primary cause of OFT al ignment defects. 
Studies have confirmed that this subpopulation of SHF cells is affected in Tbx1 null hearts 
(Fig. 14) (Parisot, Mesbah etal. 2011). 
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Figure 14: A clinically relevant subdomain of the second heart field_ Subpulmonary 
myocardium at the base of the outlet of the right ventricle (blue) in a mouse heart at E14.S 
and a human heart with tetralogy of Fallot; note the hypoplastic right ventricular outlet and 
ventricular septal defect (asterisk). Subpulmonary myocardium is severely reduced in the 
common arterial trunk of Tbx1 mutant hearts (from Kelly RG, 2012). AO , aorta; PT, 
pulmonary trunk; RA, right atrium ; RV, right ventricle ; LA, left atrium; LV, left ventricle ; SPM , 
subpulmonary myocardium ; RCA, right coronary artery; LCA, left coronary artery; CAT, 
common arterial trunk. 
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1.8 The role of Tbx1 gene during cardiac OFT development 
Tetralogy of Fallot and persistent truncus arteryosus are defects of the cardiac OFT that 
occur in 22q11.2DS patients. Formation of the OFT is a complex process that requires 
precisely regulated spatiotemporal expression of various genes in several cell types. To 
provide a sufficient number of cells to the developing heart (which grows by addition of cells 
and by proliferation of resident cells), second heart field (SHF) cells, that are cardiac 
precursors cells resident in the pharyngeal mesoderm, must proliferate at a sufficient rate 
before they enter the OFT of the heart and differentiate, because at that point, their 
proliferation rate will decrease substantially. A possible way to understand the mechanism by 
which this process is maintained is to identify genes and proteins expressed in the SHF but 
not in the OFT of the heart. Tbx1 is required for growth, alignment and septation of the OFT 
in mice. 
Prior to E11.5, there is a common outflow tract, the truncus arteriosus, which connects the 
heart to the systemic circulation. Subsequently, the outflow undergoes septation to separate 
aortic and pulmonary flows. Formally, the septum is divided into three components (from 
distal to proximal, relative to the heart): the aortico-pulmunary (AP) septum, the truncal 
septum and the conal septum (intracardiac), which is also important for the closure of the 
interventricular foramen. Tbx1 homozygous mutation causes disruption of all three 
components. leading to truncus arteriosus communis (TAC). The most proximal component 
of the outflow septum, the conal septum, is also severely affected in Tbx1 homozygous 
mutants. In these mutants at term, the single arterial orifice is connected exclusively to the 
right ventricle, while the left ventricle communicates to the right ventricle through a large 
ventricular septal defect (VSD) (Vitelli, Taddei et al. 2002). Despite the severity of the OFT 
phenotype in Tbx1 mutants, Tbx1 protein is not found in SHF-derived cells of the OFT but 
only in the SHF (Chen, Fulcoli et al. 2009). Reports of Tbx1 gene expression in the OFT 
myocardium were mostly based on the visualization of p-galactosidase activity from a 
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Tbx1LBcZ reporter (Vitelli, Taddei et al. 2002), thus probably biased by the stability of the ~­
galactosidase protein. Tbx1 is also expressed in endothelial cells and in a subpopulation of 
a-sma-positive cells of the outer wall of the OFT (Vitelli, Taddei et al. 2002). Endothelial cells 
in the conal OFT, transform into mesenchymal cells of the outflow ridges (van den Hoff, 
Moorman et al. 1999), thus, these cells may be important for septation. Tbx1 conditional ' 
mutation in the endothelial cell and their precursors (using Tie2:Cre; Tbx1 +/- mice bred with 
Tbx1f1oxlflox mice) resulted in no cardiovascular defects other than aortic arch defects 
associated with Tbx1 haploinsufficiency (Xu, Morishima et al. 2004). Similarly, Tbx1 
conditional mutation driver by an aMHC:Cre resulted in normal cardiovascular phenotype, 
apart from the aortic arch abnormalities characteristic of Tbx1 haploinsufficiency (Xu, 
Morishima et al. 2004). 
Therefore, Tbx1 is not required in resident, differentiated OFT cells, but being expressed in 
SHF cells, conditional deletion of Tbx1 in cardiac precursors cells, using Nkx2.sCra/+ mice, is 
sufficient to recapitulate the OFT abnormalities found in Tbx1-1- mutants (Xu, Morishima et al. 
2004). 
As Nkx2.5Cre induced recombination in pharyngeal mesoderm, as well as in pharyngeal 
endoderm and ectoderm, conditional deletion of Tbx1 specifically in restricted tissues was 
addressed to identify the tissue(s) in which Tbx1 is required for cardiac OFT development. 
Mesodermal deletion of Tbx1, using Mesp1cre, causes a cardiovascular phenotype very 
similar to that observed in Tbx1-1- embryos. In particular, conditional mutants at term had 
TAC, VSD, as well as aortic arch defects. At E10.5, conditional embryos presented with 
hypoplasia of the 2nd pharyngeal arches, loss of the 3rd, 4th and 6th pharyngeal arches and 
PMs, and severe hypoplasia of the pharynx. RNA in situ hybridization with a marker of 
pharyngeal pouch endoderm, showed no labeling of the 2nd and 3rd pharyngeal pouches of 
conditional mutants, suggesting that Tbx1 in the mesoderm regulates a signaling pathway 
required for pharyngeal endoderm development (Zhang, Huynh et al. 2006). To confirm that 
Tbx1 mesodermal expression is necessary for a correct development of the cardiac OFT, 
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Tbx1 expression was restored in this tissue and its reactivation rescued completely the OFT 
defects, the formation and remodeling of the 3rd and 6th PAAs, the hypoplasia of the 2nd 
pharyngeal arch, and the 2nd and 3rd pharyngeal pouches, but did not rescue the 4th 
pharyngeal arch and the 4th PAA aplasia (Zhang, Huynh et al. 2006). The crucial time 
requirement for Tbx1 in mesoderm, in the development of the cardiac OFT is between E8.5 
and E9.5, as demonstrated by timed fate mapping of Tbx1-expressing cells (Xu, Cerrato et 
al. 2005). This relatively late and narrow time-window is not consistent with a crucial role in 
the early SHF cell populations located medially to the cardiac crescent; rather, these findings 
are consistent with a crucial role of Tbx1 in regions that provide precursors destined to the 
OFT at a later stage, such as the splanchnic mesoderm (Kelly, Brown et al. 2001). 
To understand the earliest molecular consequences of Tbx1 loss of function in the 
mesoderm, conditional mutants (showed above) were examined for cell proliferation at a 
stage shown to be crucial for Tbx1 function in cardiac OFT development, i.e. E8.5. A strong 
reduction in cell proliferation was found In the region of the SHF and adjacent splanchnic 
mesoderm that normally expresses Tbx1 (Zhang, Huynh et al. 2006; Chen, Fulcoli et al. 
2009). Such reduced proliferation explained the strongly reduced cellularity in the pharyngeal 
arches and the cardiac OFT defects. The Tbx1 pro-proliferative activity was affected, at least 
in part, by regulating FGF signaling in a cell-autonomous manner, positively modulating the 
expression of fibroblast growth factor 8 (FgfB) , Fgf10 and Fgf receptor 1 (Fgfr1). fgfB and 
Fgf10 both drive SHF proliferation (Watanabe, Zaffran et al. 2012; Park, Ogden et a!. 2006). 
and Tbx1 positively modulates FgfB and Fgf10 expression in the SHF mesoderm (Hu, 
Yamagishi et al. 2004). Studies have shown that Tbx1 binds to the first intron of Fgf10 to 
regulate its expression in the SHF (Watanabe, Zaffran et al. 2012). The loss of Tbx1 disrupts 
the expression of Fgfr1 (Park, Ogden et al. 2006), and Crkl1 interacts with Fgfr1 to mediate 
FgfB signaling (Moon, Gurls et a!. 2006). 
SHF cells maintain an undifferentiated precursor state until they migrate into the heart (Cai, 
Liang et al. 2003). Therefore, It is important to maintain a proliferating as well as an 
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undifferentiated progenitor cell pool in the SHF for appropriate OFT development. In addition 
to regulating cardiac precursors proliferation, Tbx1, similarly, controls the differentiation of 
these cells, keeping theme in an undifferentiated precursor state. For this end, Tbx1 supports 
the expression of several genes to maintain a balance between proliferation and 
differentiation of progenitor cells in the SHF. 
Tbx1 maintain the undifferentiated cardiac precursors state in different manners. Studies 
have shown that Bmp signaling promotes cardiac OFT differentiation (Wang, Greene et aJ. 
2010). Smad1, a member of the Bmp pathway, is a critical negative regulator of SHF 
proliferation in vivo, and its ablation in the SHF enhances cell proliferation (Prall, Menon et aJ. 
2007). Tbx1 binds to Smad1 and negatively modulates the Bmp-Smad Signaling pathway by 
Interfering with the Smad1-Smad4 interaction (Fulcoli, Huynh et aJ. 2009). This regulation by 
Tbx1 is necessary to maintain the cardiac progenitor population in the SHF, and to prevent 
the premature myocardial differentiation. 
Tbx1 inhibits SHF differentiation by antagonizing not only the Bmp pathway but also the 
activities of Mef2c and serum response factor (Srf). Mef2c is key transcription factor in OFT 
myocardial differentiation (Pane, Zhang et aJ. 2012), and Srf is a myogenic transcription 
factor that regulates muscle differentiation. Tbx1 did not regulate Srf transcriptionally, but it 
interacts with Srf protein, decreasing its stability and Increasing proteasome-mediated 
degradation of Srf protein levels (Chen, Fulcoli et al. 2009). Together, these findings indicate 
that Tbx1 is precisely regulated in the SHF, and that it maintains the balance between the 
cardiac progenitor population and differentiating cardiac cells by interacting with pro-
proliferation and pro-differentiation factors during development of the OFT. 
Recent studies identified a novel function of Tbx1, to interact with chromatin modifiers during 
development of the cardiac OFT. Baf60a, a component of the SWI-SNF-like BAF chromatin-
remodeling complex, Is a key cofactor for Tbx1 function in the cardiac progenitors. Wnt5a 
has been found to be a novel and important transcriptional target of Tbx1, whose regulation 
Is mediated by the recruiting of Baf60a and histone modifier Setd7 to the gene. Wnt5a 
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encodes a ligand of the non-canonical Wnt pathway, whose mutation leads to defects in OFT 
development. Combined loss of Tbx1 and Wnt5a genes caused a severe hypoplasia of the 
SHF-derived heart segments, leading to a much more severe phenotype than that caused by 
loss of the individual genes (Chen, Fulcoli et at 2012). These findings demonstrated that 
Tbx1 is able to regulate OFT development by interacting with chromatin modifiers. 
1.9 p53: not only 8 tumor suppressor 
Since its discovery in 1979, the role of the p53 protein in cancer has been studied intensively 
(Levine and Oren 2009). p53 is a crucial tumor suppressor, implicated in the control of cell 
proliferation and tumor progression. Allelic losses and mutations in the Trp53 genes are 
frequently observed In many types of tumors. Unequivocal confirmation of the crucial role for 
p53 in tumor suppression was demonstrated by the completely penetrant cancer phenotype 
of Trp53 null mice (Kenzelmann Broz and Attardi 2010). 
Although research on p53 has focused on cancer for many years, it is now appreciated that 
p53 has a much more pleiotropic role as a stress sensor, and that p53 has functions in 
various physiological and pathological processes (Vousden and Lane 2007). 
Most mice missing both functional copies of Trp53 exhibit normal prenatal and postnatal 
development (Donehower, Harvey et al. 1992). The developmental viability of Trp53 null 
mice was initially surprising, given the importance of p53 as a known cell-cycle checkpoint 
control protein and its high levels of expression in early phases of embryonic development 
(Schmid, Lorenz et al. 1991). The Trp53 null mice were developmentally normal in every 
measurable way, except that they were predisposed to early tumor development (primarily 
lymphomas and sarcomas). An initial indication that p53 has functions that extend beyond 
tumor suppression came from the observation that a fraction of Trp53'·mouse embryos 
display developmental aberrations, including prominent defects in neural-tube closure and 
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consequent exencephaly (Armstrong, Kaufman et al. 1995; Sah, Attardi et al. 1995). Further 
examination of Trp53-1- adult mice recently revealed a role for p53 in embryo implantation, 
indicated by the dramatically low fertility rates observed in female Trp53"'- mice (Hu, Feng et 
a!. 2007)_ Additional abnormalities have been described in the Trp53 null embryos, including 
upper incisor fusion, ocular abnormalities and polydactyly of the hindlimbs (Armstrong, 
Kaufman et al. 1995). The incomplete penetrance might be due to the interaction of genetic 
and environmental factors. Sah et al. (Sah, Attardi et al. 1995) demonstrated that 129/Sv 
Trp53 null embryos had a higher rate of exencephaly than null embryos of mixed 129/Sv-
C57BU6 background, suggesting that strain-specific modifier genes may influence the 
degree of penetrance. The discovery that an absence of p53 activity can lead to a fatal 
defect in a significant fraction of embryos clearly implicates p53 as an important factor in 
development. 
In addition to its role in development and aging, recent studies have elaborated newly 
identified functions of p53 in several other physiological contexts. p53 is involved in 
restricting the self-renewal of several types of stem cells, including neural stem cells and 
hematopoietic stem cells (Melet/s, Wirta et al. 2006; Cicalese, Bonizzi et al. 2009). 
Furthermore, several groups have reported enhanced effiCiency of cellular reprogramming of 
somatic cells to induce pluripotent stem (iPS) cells In the absence of p53, implicating p53 In 
the maintenance of a differentiated state (Krizhanovsky and Lowe 2009). 
1.10 p53 and development In the context of other genetic deficiencies 
As a transcription factor, p53 has been demonstrated to regulate a number of genes involved 
In cell-cycle control, apoptosls, and checkpoint function (Gottlieb and Oren 1996; Ko and 
Prives 1996; Levine 1997). Moreover, p53 appears to bind an amazingly large number of 
proteins Involved In growth control, DNA repair and transcriptional regulation. Given the 
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many molecular functions and interactions mediated by p53, it is perhaps not surprising that 
In the last few years it has been shown to influence developmental processes in the context 
of other genetically deficient knockout mice. Usually, this interaction takes the form of partial 
or complete rescue of an embryonic lethal phenotype following crosses of Trp53-deficient 
mice to a mouse deficient in a growth regulatory or DNA repair-related gene. Such crosses 
have provided important new inSights into the interactions of Trp53 and other genes during 
differentiation, development, DNA repair and growth control. 
The most dramatic example of phenotype rescue by Trp53 -deficiency was observed when 
Mdm2 -deficient mice were crossed to Trp53 -deficient mice (Jones, Roe et al. 1995; Montes 
de Oca Luna, Wagner et al. 1995). The Mdm2 gene encodes a protein which directly binds to 
p53 and inhibits its normal transcriptional activation and tumor suppressor functions at least 
in part through p53 degradation. It has been found that Mdm2 nullizygosity resulted in early 
embryonic lethality at roughly 6.5 days gestation (Jones, Roe et al. 1995; Montes de Oca 
Luna, Wagner et al. 1995). However, after crosses of Trp53 -deficient mice to Mdm2 
heterozygous mice, double null Trp53 and Mdm2 mice were found to be completely viable 
with no obvious developmental abnormalities. Interestingly, rescue of the Mdm2 null 
embryoniC lethality could not be achieved by substituting p21WAF11CIP1 nullizygosity for 
Trp53 nulllzygoslty, suggesting that abrogation of the G1 arrest checkpoint function of p53 
was not involved In the (Montes de Oca Luna, Amelse et al. 1997». 
Another example of rescue by Trp53-deficlency was illustrated in the Rad51- Trp53 knockout 
mouse crosses (Lim and Hasty 1996). 
Nulllzygous embryos deficient in the Brca1 and Brca2 tumour suppressors have also been 
partially rescued by the absence of p53 (Hakem, de la Pompa et al. 1997; Ludwig, Chapman 
et a!. 1997). 
Tissue-specific partial rescue by p53 deficiency was observed in A TM-null mice, the genetic 
model for the human disorder ataxia telangiectasia, characterized by various neurological 
malfunctions, infertility and increased tumour susceptibility (Barlow, Liyanage et al. 1997) 
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Trp53 deficiency, caused by germ-line mutation or by pifithrin-a, a p53 inhibitor, rescues 
neural tube defects in Pax-3-deficient Splotch (Sp/Sp) embryos (Pani, Horal et al. 2002) and 
prevented the defective cardiac neural crest migration and apoptosis in Pax3-deficient 
embryos, restoring proper development of cardiac outflow tract (Morgan, Lee et al. 2008). 
Inhibition of p53 also prevents cyclin G 1-driven apoptotic elimination of neural crest cells 
while rescuing the craniofacial abnormalities associated with mutations in Tcof1 (Jones, Lynn 
et at 2008). 
Together, these findings underscore the importance of p53 in diverse pathological states and 
indicate that p53 inhibitors might be promising therapeutics for these diseases. 
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CHAPTER 2 - AIM OF THE RESEARCH PROJECT 
2.1 To establish the effect of Tbx1 on the cell proliferation 
Tbx1 has a critical role in splanchnic mesoderm of the Second Heart Field (SHF), 
which gives cardiomyocyte progenitor cells of the OFT and right ventricle. It was further 
observed that the loss of function of Tbx1 in the SHF is associated with a reduction of cell 
proliferation. The reduced cell proliferation in the SHF is associated with reduced contribution 
of cells to the OFT and, consequently, to a reduced number of muscle cells. 
To understand the functional and molecular basis of Tbx1 action to promote cell proliferation 
I analyzed cell proliferation and more specifically cell cycle, modulating Tbx1 expression, and 
I analyzed molecular markers that are direct or indirect Tbx1 targets, necessary to promote 
cell proliferation. 
2.2 Rescue strategies In a mouse model of DIGeorge syndrome. 
Deletion 22q11.2 syndrome Is the most frequent known microdeletion syndrome and 
is associated with a highly variable phenotype. This syndrome constitutes a major cause of 
congenital heart disease (CHD), accounting for about the 5% of all CHD cases among live 
births. Of the about 30 commonly deleted genes, Tbx1 is the only gene that, after an 
extensive functional analysis in the mouse, has been found to be haploinsufficient with a 
convincingly similar phenotype to the human syndrome. So it is a very frequent and 
complicated syndrome, and although there have been many studies related to the role of 
Tbx1 during development, they do not yet arrived to the identification of drugs that could 
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rescue the mutant phenotype. I therefore, searched for genetic and pharmacologically 
strategies that could counteract the effects of reduced dosage of Tbx1. 
The transcription factor p53, which is encoded by the Trp53 gene, has pro-differentiation and 
anti-proliferation activities in stem cells, and its loss of function facilitates reprogramming of 
differentiated cells. Therefore, we asked whether Tbx1 and Trp53 interact during 
cardiovascular development. 
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CHAPTER 3 - MATERIALS AND METHODS 
3.1 Mouse mutant lines 
Lines Tbx1'acZ (here referred to as Tbx1") (Lindsay, Vitelli et al. 2001), Tbx1n802 
(Zhang, Huynh et al. 2006) and Trp5:r mutant (Jacks, Remington et al. 1994) where 
maintained in our SPF colony in a mixed CS7BI6/129SvEv background and genotyped 
according to the original reports. For timed crosses, developmental stage was evaluated by 
considering the morning of vaginal plug as EO.S. Pifithrin-a (Enzo Life Sciences, #BML-
GR32S) was diluted in PBS and injected at 2.2 mg/kg body weight. Injections were carried 
out intraperitoneally at E7.S, E8.S, and E9.S. Controls were injected with the same amount of 
carrier, but without drug. 
Mouse were genotyped by PCR using DNA extracted from tail biopsies, using following 
primer pairs: 
Tbx1,acZ: Tbx1 WT -F (5' -AGTCTGGGGACTCTGGAAGG-3') 
Tbx1 WT -R (S'-AAGGCAGATCCTGCTACACC-3') 
Tbx1 Tar2R (S'-TCGACTAGAGCTIGCGGAAC-3') 
Tbx1N802: Tbx1Ne02-F (5'- GACTAGAGACAGGGGCATGG-3') 
Tbx1Neo2-TF (5'- GCCAGAGGCCACTIGTGTAG-3') 
Tbx1 Neo2-R (5'- AGGCTGGGA TICCAAAAGAC-3') 
Trp53: TrpS3 WT -F: (5' -ACAGCGTGGTGGTACCTT AT -3') 
TrpS3 Mut-F: (S'-CTATCAGGACATAGCGTIGG-3') 
TrpS3 WT -R: (S'-TATACTCAGAGCCGGCCT -3') 
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PCR products have been separated on 2% agarose gels. 
3.2 Culture and In vitro transfectlon of mES cells and C2C12 myoblasts 
mES cells were culture in Glasgow minimal essential medium (GMEM) supplemented 
with 15% fetal bovine serum (FBS), 1 mM sodium pyruvate, 1 X non-essential amino acids 
(NEAA), 1 : 500 b-mercaptoethanol (BME) and 1000 U/mL leukemia inhibitory factor (mLlF), 
on gelatin-coated dishes. For Tbx1 over-expression, I used the Amaxa nucleofector (using 
the standard protocol for stem cells); cells were collected 24 h after transfection for RNA 
extraction. 
Mouse C2C12 myoblasts were cultured in OM EM supplemented with 10% FBS and 105 cells 
were plated in 6 wells plate. The next day, cells were transiently transfected using 
Lipofectamine 2000 according to the manufacturer's instructions; cells were collected 24 h 
after transfection for RNA extraction. 
3.3 Culture and differentiation of P19CL6 cell line 
P19CL6 cells were grown in MEM Eagle Alpha Modification (Sigma Aldrich, #M4526) 
supplemented with 10% FBS. To induce cardiomyocyte differentiation, I used a published 
protocol (Mueller, Kobayashi et al. 2010). Briefly, 3x106 P19CL6 cells were plated on a 100 
mm tissue culture dish. The next day (day 0 of differentiation), cells were treated with 10 
tlmol/L 5-Azacytidine (Sigma Aldrich, #A2385) for 24h, and subsequently, cells were 
incubated with 1% OMSO. 
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3.4 Silencing of Trp53 by siRNA 
For Trp53 silencing, P19CL6 cells were differentiated as described above. At day 0 of 
differentiation, cells were transfected with anti-p53 siRNA (Sigma, 5'-
CCACUUGAUGGAGAGUAUU-3') to knockdown p53 expression, using Lipofectamine 
RNAiMAX Reagent (Invitrogen, #13778-150) following the standard protocol. Non-targeting 
siRNA (5'- GUCGUAACGUCGAUUAUAG-3') was used for control transfections. 24 h after 
transfection, cells were transfected again at the same conditions and collected 24 h after the 
second transfection (day 2 of differentiation). mRNA expression was evaluated by 
quantitative real-time PCR and protein expression by western blotting. 
3.5 Cell cycle analysis and Proliferation assay 
For cell cycle analysis I used an inducible (Tbx1-TetOFF) system, in which the 
presence of Tetracycline (Tc) in the culture medium turns off expression of a transgenic 
construct, while the removal of Tc from culture medium, induces Tbx1 expression. 
In this experiment, Tbx1 expression was induced for 5 and 24h, cells were collected and 1.2 
x 106 cells were fixed with 70% Ethanol on Ice for 30 minutes. Samples were treated with 
RNase A, 100 "g/ml, and then stained with a DNA dye, 20 "g/ml propidium iodide (PI), and 
after at least 30 minutes, they were analyzed by flow cytometry (Becton Dickinson 
FACSAria) to measure DNA content. 
For proliferation assay, C2C12 cells were labeled with 10 .... moUl 5-(and-6)-
Carboxyfluorescein Diacetate, Succinimidyl Ester (5(6)-CFDA, SE; CFSE), (Life 
Technologies, # C1157) and 105 cells were plated in 6 wells plate, grown in Dulbecco's 
Modified Eagle Medium (Sigma, #05671) supplemented with 10% fetal bovine serum. The 
next day, cells were transfected with a Tbx1 expression vector or with empty vector (with 
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Lipofectamine 2000, Invitrogen #11668-019, using the standard protocol). Cells where 
collected after 24h and analyzed by flow cytometry. 
3.6 RNA extraction. reverse transcription and q real-time peR 
RNA was isolated from whole E8.5 WT, Tbx1+1., Trp53+1- and Tbx1+1-;Trp53+1- embryos, 
from C2C12 cells or from P19CL6 cells (Mueller, Kobayashi et at 2010) using Trizol reagent 
(Invitrogen, #15596018). Prior to procede to reverse transcription, RNA samples were 
treated with DNAse I (Invitrogen). First strand cDNA synthesis was performed on 300 ng of 
RNA from E8.5 embryos and 1 Jlg of RNA from cultured cells using the High-Capacity cDNA 
Reverse Transcrition Kit, with oligo (dT)12-18 and random primers (Applied Biosystems, 
#4368814). mRNA expression was evaluated by quantitative real-time PCR carried out using 
FastStart Universal SYBR Green (Roche, #04913850001), on a 7900HT Fast Real-Time 
PCR System (Applied Biosystem). All samples were run in triplicates, by using 2 JlI of cDNA 
(diluited 1:10 in water) In 20 ~I reaction volumes. The cycle threshold (Ct) was determined 
during the geometric phase of the PCR amplification plots, as recommended by the 
manufacturer. Relative differences in transcript levels were quantified using the AACt method 
and normalized to Gapdh expression reference. All PCR were performed using primers that 
amplify across an intron. The following primer sequences were used: 
Cdkn1 a-F: 5'-CTGCCCAAGGTCTACCTGAG-3' 
Cdkn1 a-R: 5'-TGCAGAAGACCAA TCTGCGC-3' 
Cdkn1 b-F: 5'-GGAGCAGTGTCCAGGGATGAGG-3' 
Cdkn1b-R: 5'-GGCCCTTTTGTTTTGCGAAG-3' 
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Gapdh-F: 5'-TGCACCACCAACTGCTT AGC-3' 
Gapdh-R: 5'-TCTTCTGGGTGGCAGTGATG-3' 
Gbx2-F: 5'-GCTGCTCGCTTICTCTGC-3' 
Gbx2-R: 5'-GCTGT AA TCCACATCGCTCTC-3' 
Smad7-F: 5'-AACGAGAGTCAGCACTGCCA-3' 
Smad7-R: 5'-GAAGGTGGTGCCCACTTICA-3' 
Tbx1-F: 5'-CTGACCAA T AACCTGCTGGATGA-3' 
Tbx1-R: 5'-GGCTGATATCTGTGCATGGAGTT -3' 
Trp53-F: 5'- GCAACTATGGCTTCCACCTG-3' 
Trp53-R: 5'-TT A TTGAGGGGAGGAGAGTACG-3' 
Wnt5a-F: 5'-CTCCTTCGCCCAGGTTGTTATAG-3' 
Wnt5a-R: 5'-TGTCTTCGCACCTTCTCCAA TG-3' 
3.7 Ink Injection and histological staining 
Ink Injection was performed on E10.5 embryos, which were collected and injected 
intracardially with India ink, and fixed in 4% paraformaldehyde. Embryos were then 
dehydrated and cleared in 1:1 benzyl benzoate:methyl salicylate. 
Hearts collected from E18.5 embryos were fixed in 4% paraformaldehyde over night 
at 4°C, embedded in paraffin and cut into 10 .... m sections. Histological staining was 
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performed using eosin and counterstaining was performed using Nuclear Fast Red (Vector 
Lab .• #H-3403). 
3.8 Immunohistochemistry 
For proliferation studies. E9.5 embryos were fixed in 4% paraformaldehyde over night at 4°C. 
embedded in paraffin and cut into 7 11m sections. Immunohistochemistry on 
paraformaldehyde fixed paraffin sections was performed as follows. Sections were 
deparaffinized by two 10 minutes incubations in BioClear (a synthetic form of Xylene). 
followed by rehydratation in ethanol series. beginning at 100% ethanol and ending in 50% 
ethanol. This was followed by heat mediated antigen retrieval in 0.01 M citrate buffer. pH 6.0. 
for 5 minutes at 100% microwave power followed by 15 minutes at 70% power. Antigen 
retrieval methods serve to break the methylene bridges formed during fixation which cross-
links proteins and therefore mask antigen sites. After antigen retrieval. sections were blocked 
in 3% bovine serum albumin (BSA). 5% newborn calf serum (NBCS). 20mM MgCI2• 0.3% 
Tween-20. 1 % milk for 1 hr and then incubated with primary antibody. anti phospho-Histone 
H3 (Ser10). diluted 1 :200 in blocking solution over night at 4°C. Sections were washed in 
PBS and incubated for 1 hour In horseradish peroxidase (HRP)-conjugated anti-rabbit IgG 
(Vector Laboratories) diluted 1 :200 In blocking solution. Finally. samples were stained with 
DAB (Vector Laboratories). I counted Phospho-Histone H3 (PH3) positive and negative cells 
in the SHF (at least 2000 cells per embryo) of three somite-matched embryos per genotype. 
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3.9 Western blotting 
Total proteins were extracted after cell lysis with the RIPA buffer (1 % NP40, 0.5% NaOoc, 
150 mM NaCl, 0.1% SOS, 50mM Tris HCI pHS.O, 1 X protease inhibitor (Roche». Nuclear 
and cytoplasmic proteic extracts were prepared using the NE- PER Nuclear and Cytoplasmic 
Extraction Reagents (Thermo Scientific). lysates were incubated for 3 min at 95°C to allow 
protein denaturation. The concentration of protein was determined using a Bredford Protein 
Assay kit (Biorad) according to the manufacturer's instructions. Equal amount of proteins 
were loaded on gel and separated by SOS-PAGE, transferred to a Protran Nitrocellulose 
Hybridization Transfer Membrane 0.2 ~m pore size (Amersham), and blocked for 1 h at room 
temperature in TBST (150 mM NaCl, 10 mM Tris- HCI, pH 7.4, and 0.05% Tween)-powdered 
milk. The membranes were incubated overnight at 4°C in primary antibodies diluted in TBST-
5% milk. The primary antibodies were rabbit anti-TBX1 (Abeam, 1 :500), rabbit antl-p53 
(Santa Cruz Biotechnology, 1:1000), monoclonal anti-Smarcd1 antibody (BO Bioscience, 
1:1000), and rabblt-anti-beta-Actin (Sigma-Aldrich, 1:10000). Next, membranes were rinsed 
3 times with TBST for 5 min each, and then they were incubated for 1 h at RT with 
horseradish peroxidase (HRP)-linked secondary antibodies (diluted in TBST-5% milk). The 
secondary antibodies were: HRP-conjugated anti-rabbit and anti-mouse antibodies (GE 
Healtheare, 1:5000 and 1:10.000). Membranes were rinsed 3 times with TBST for 5 min 
each, and the HRP-derived signal was detected using the Amersham ECl and ECl Plus 
Western Blotting Detection Reagents (GE Healtheare). 
3.10 Co-lmmunopreclpltatlon 
P19Cl6 cells (2x105) were plated on a 100 mm culture dish. The next day, cells were 
transfected with a Trp53 expression vector or with empty vector. Cells were collected after 
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48h, and 200 Ilg of nuclear extracts were immunoprecipitated with 2 Ilg of an anti TBX1 
antibody (Abcam, #ab18530), or with 2 Ilg of rabbit IgG (Santa Cruz Biotechnology, #2027) 
as a negative control and then incubated with 20 III of Protein AJG PLUS Agarose (Santa 
Cruz Biotechnology, #sc-2003) at 4°C over night. The samples were washed 7 times with 
IPP150 buffer (10 mmollL Tris-HCI, pH 8.0, 150 mmollL NaCl, 0.1 % NP-40) and 
resuspended in SDS sample buffer. 10% of input and immunoprecipitated samples were 
used for Western blot analysis. We used an anti p53 antibody (Santa Cruz Biotechnology, 
#sc-6243) and an anti Smarcd1 antibody (BD Bioscience, #611728). 
3.11 Chromatin Immunopreclpltatlon 
For ChiP assay, P19CL6 cells were collected at day 2 of differentiation. Cells were 
fixed with 1 % formaldehyde diluted in PBS and Buffer A (Transcription Factor ChiP Kit 
reagent, Diagenode, #Kch-redTBP-012) at room temperature for 10 min. The cross-linking 
reaction was stopped using 0.125 mol/L glycine at room temperature. Cells were collected by 
scraping with cold PBS, cells were then lysed and chromatin was sonicated to obtain 150-
350 bp fragments using S2 Covaris System (Duty Cycle: 5%, Intensity: 3, Cycles/Burst: 200, 
Cycles: 5, Cycles time: 60 sec, Temperature: 4°C). 6 JA.g of sonicated chromatin was 
immunoprecipitated with 5 JA.g of a TBX1 antibody (Abeam, #ab18530), 5 JA.g of a p53 
antibody (Santa Cruz Biotechnology, #sc-6243 X), or 5 JA.g of Rabbit Control IgG (Abeam, 
#ab46540). Samples were then incubated with 30 JA.I of Pre-blocked protein AJG coated 
beads at 4°C over night. After incubation, the samples were washed and DNA-proteln-
antibody complexes were eluted in Buffer F of the above mentioned kit, at room temperature 
for 25 min. To reverse cross-linking, samples were incubated at 65°C over night. 
Phenol/chloroform-purified and ethanol-precipitated DNA was resuspended in 200 III of H20 
and equal DNA amounts of input and immunoprecipitated DNA were subjected to qPCR 
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amplification. ChiP signals were normalized to that of an internal control amplimer selected 
from an ORF-free region of mouse chromosome 14 (Chen, Fulcoli et al. 2012). 
The following primer sequences were used: 
Gbx2TBE1-F: CTAGGAGGTGCCTCTGAGTTCT 
Gbx2TBE1-R: ACCACCATGGAGAGGCCCT AA 
Gbx2TBE2-F: TCACAGCACTAAAGTTAGAGAGG 
Gbx2TBE2-R: GCCTTGGAAGAGCGACCTGTA 
Gbx2TBE3-F: GAGAGCGTTGAGTTCTGAGTGC 
Gbx2TBE3-R: GGACCGTGAAAAGAGTCCAGC 
Gbx2TBE4-F: CAGGGAGGACGGGATGGAA T AA 
Gbx2TBE4-R: GCTGA TT AA TGAGACCCACGAG 
Gbx2p53BE1-F: A TTGCGGCGAAAGGAAAGT 
Gbx2p53BE1-R: CCACGAAAGGATCCCA TTTT 
Gbx2p53BE2-F: GTCCTGCAGTCCGTCGTC 
Gbx2p53BE2-R: GAGGAGCGCGA TIT AAAGGT 
Gbx2p53BE3-F: TCGGGGATACGCAGTCTT AG 
Gbx2p53BE3-R: TITAGTGCTGTGACCGAAGC 
Gbx2p53BE4-F: GCACCCATGCATTCCATC 
S9 
Gbx2p53BE4-R: GCCGATGCCGAAAA TTCTA 
INT-XIV-1 F: nCnGTCCACAGCCCTCn 
INT-XIV-1 R: TGGTGGAAGAGGAGACATCC 
3.12 ChiP and Western blotting 
For ChIP-WB, sonicated chromatin (obtained as described above) was immunoprecipitated 
with 10 ~g of the TBX1 antibody, 10 ~g of the p53 antibody, or 10 ~g of Control Rabbit IgG; 
all antibodies were conjugated with Dynabeads Protein G (Novex by Life Technologies, 
#100040). To avoid co-elution of antibodies, they were then cross-linked to the Dynabeads 
using 20 mmol/L Dimethyl pimelimidate dihydrochloride (Sigma Aldrich, 08388), before 
continuing with immunoprecipitation. Approximately 50 ""g of sonicated chromatin was 
immunoprecipitated at 4°C over night. Samples were then washed 6 times with cold PBS-
0.01 % Tween-20 and DNA-protein complexes were eluted in 50 ""I of 0.1 mol/L Glycine, pH 
2.6 at room temperature, for a total of 3 elutions. Reverse cross-linking was done at 95°C for 
30 min in 50S sample buffer. 10% of input and immunoprecipitated samples were detected 
using Western blot analysis. 
3.13 Cloning. plasmlds 
We have previously described the pCDNA-Tbx1-3xHA expression vector (Chen, Fulcoli et al. 
2012). pCAG-Trp53 expression vector was kindly provided by Prof. A. Fusco (University 
FederiCO II, Naples). 
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For luciferase assay, I cloned a 1500 bp fragment of Gbx2 3' gene into pGL3 promoter vector 
(Promega). Briefly, I amplify this fragment with the following primers: 
Gbx2Luc-F: 5' -CCCCCATCAGAA TT AA TCA TTG-3' 
Gbx2Luc-R: 5'-GAAGAGCGACCTGT AAAGCG-3' 
The fragment was cloned into pCRII-TOPO and plasmid was purified from positive DH5a 
bacterial colonies and digested with Kpnl and Xhol restriction enzymes. The same restriction 
enzymes were used to digest pGL3-Promoter Vector, in which the insert was cloned. Ligation 
reaction was performed by using T4 DNA ligase enzyme (New England Biolabs) and 
samples were incubated over night at 16°C. 
3.14 Luclferase assay 
For luclferase assay, human JEG3 choriocarcinoma celFls were plated in 24-wells and 
transfected with X-tremeGENE DNA Transfection Reagent (Roche) according to the 
manufacturer's instructions. Increasing amount of Trp53 expression vector and equal amount 
of Gbx2Luc reporter construct were always co-trasfected with a pCMV-p-Gal expression 
vector (Clonotech). 24 h after transfection, cell extracts were prepared and activities of p_ 
galactosidase and firefly luciferase were measured using the Luciferase Assay System 
(Promega) and the Beta-Glo Assay System (Promega) respectively, on a Sirius Single Tube 
Luminometer (Titertek Berthold). Relative luclferase activity (firefly luciferase for reporter and 
b-galactosidase for normalization of transfection efficiency) was measured following 
manufacturer's instructions (Promega); to correct for transfection efficiency, the luciferase 
activity was divided by the p-galactosldase activity in every case. The data represent the 
means and standard deviations of six independent experiments. 
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CHAPTER 4 - RESULTS 
4.1 Tbx1-enhanced cell proliferation Is associated with down regulation of p21 and p27 
expression In cultured cells. 
Tbx1 alters cell proliferation through different pathways, for example, by positive regulation of 
the FGF-MAPK pathway (Vitelli, Lania et al. 2010) or negative regulation of BMP-SMA01 
signaling (Fulcoli, Huynh et al. 2009). Increased proliferation in response to increased Tbx1 
dosage occurs in several cell types in culture, for example differentiating mouse ES cells 
(Chen, Fulcoli et al. 2009), or undifferentiated mouse ES cells overexpressing Tbx1. I 
performed cell cycle analysis using an inducible (Tbx1-TetOFF) system previously 
established in our laboratory using the ROSA-TET system described by Masui et al. (Masui, 
Shlmosato et al. 2005). The Tet-off system is based on a Tc-regulatable transactivator (tTA), 
which induces transcription In the absence of Tc or its analog doxycycline (Oox) through 
binding to the hCMV-1 promoter. This promoter is composed of a Tc-responsive element 
(TRE) followed by a minimal promoter of the human cytomegalovirus (hCMV) immediate 
early gene. The tTA protein is a fusion protein composed of the TRE-binding domain of Tc 
repressor protein and the herpes simplex virus VP16 activation domain (Gossen and Bujard 
1992). The ROSA-TET system allows researchers to establish ES cell lines carrying a Tc-
regulatable transgene at the ROSA26 locus. This locus was first described as a gene-
trapped locus on chromosome 6 (Zambrowlcz, Imamoto et al. 1997). This locus is now 
regarded as one from which proteins can be expressed ubiquitously at a moderate level. A 
knock-in strategy into the ROSA26 locus, however, still requires homologous recombination. 
The ROSA-TET system is based on a knock-in step of a construct carrying both 10xP and its 
mutant sequences (loxPV) into the ROSA26 locus, followed by a subsequent exchange step 
that introduces a cONA to be Tc-regulated to the locus, using the recombinase-mediated 
cassette exchange reaction (Fig. 15A). 
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Figure 15: Development of the ROSA-TET system and induction of expression in that. 
(A) Experimental strategy to generate the ROSA-TET locus and the desired locus (Masui , 
Shimosato et al. 2005), (B) Schematic representation of the induction of Tbx1 expression . 
(C ) qRT-PCR on mRNA from EBRTcTbx1 cells grown in ES medium with and without Tc. 
In our laboratory. an exchange vector carrying the Tbx1 cDNA was cotransfected along with 
a Cre-expression vector into EBRTcH3 cells which had been derived from EB3 cells by the 
knock-in step . to establish an ES cell line (named EBRTcTbx1) expressing Tbx1 under the 
control of the ROSA26 promoter in a Tc-dependent manner (Fig . 15B). In the absence of Tc 
in cultu re medium. tTA binds to the hCMV-1 promoter, inducing expression of Tbx1 , 
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By qRT-PCR on mRNA from cells cultured for 6h , 24h, 48h and 72h in the absence of Tc, we 
observed a Tbx1 mRNA level increased during time course , confirming the efficiency of the 
system (Fig . 1SC). 
Cell cycle analysis on this inducible system was performed after Sh and 24h of Tbx1 
expression . Results showed that Tbx1 overexpression is associated with an increase of the 
percentage of cells in Sand G2/M phases, compared to control cells (Fig. 16). 
Tb 1 
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Figure 16: Tbx1 enhances cell cycle. 5h and 24h of Tbx1 expression increases the 
percentage of mES cells in Sand G2/M phases. 
Similar results were obtained on mouse myoblastoid C2C12 cells analyzed by cell 
proliferation assay. Cells were stained at the moment of culture with Carboxyfluorescein 
Succinimidyl Ester (CFSE), a fluorescent cell staining dye capable to bind to the intracellular 
and membrane bound proteins. This dye can be used to monitor cell proliferation , due to the 
progressive halving of CFSE fluorescence within daughter cells following each cell division. 
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In my experiment, Tbx1 was transiently over-expressed in C2C12 cells and after 24h from 
transfection , cells were analyzed by flow cytometry. Resu lts showed that Tbx1 over-
expressing cells were in the fifth generation compared to the control cells that were in the 
fourth generation (Fig . 17 A). 
Then , I performed molecular analysis of cell cycle regulators . The expression levels of the 
positive regulators, Cyclin A 1, Cyclin 01 , Cyclin 02, Cyclin 03 and Cyclin E1 was not 
changed , while the express ion analysis of negative cell cycle regulators , such as Cdkn1a , 
Cdkn1b, Cdkn2a , Cdkn2b, Cdkn1c showed that genes Cdkn1a and Cdkn1b , which encode 
the cell cycle inhibitors p21 and p27 , respectively , are down regulated after transfection of 
Tbx1 (Fig. 17B-0 ). Up regulation of p21 in response to loss of Tbx1 was also noted during 
tooth bud development (Cao, Florez et al. 2010). These findings suggest that the positive 
reg ulation of cell cycle by Tbx1 may function through negative regulation (d irect or indirect) of 
cell cycle inhibitors. 
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Figure 17: Tbx1 enhances cell proliferation and suppresses cell cycle inhibitors 
expression in cultured cells. (A) Cell cycle analysis of C2C12 cells control (EV) and 
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transfected with a Tbx1 expression vector (Tbx1). Transfected cells proliferate faster than 
control cells. 
(B-D) Quantitative real time PCR evaluation of expression of the genes indicated with and 
without Tbx1 overexpression in C2C12 cells (B) and in mouse embryonic stem (mES) cells. 
In all cases, the expression is significantly reduced after transfection of a Tbx1-expressing 
vector. *: P= 0.039; **: P= 0.018. Error bars indicate SEM of experiments done in triplicate. 
4.2 Epistatic genetic Interaction between Trp53 and Tbx1. 
Tbx1 regulates the homeostasis of cardiac progenitor cells (Chen, Fulcoli et al. 2009), 
self renewal of stem cells of the hair bulb (Chen, Fulcoli et al. 2012), and stem cells of the 
tooth bud (Cao, Florez et al. 2010), suggesting that the gene plays a role in the maintenance 
of a pool of stem/progenitor cells through promotion of cell proliferation and inhibition of 
differentiation in different tissues. We reasoned that p53 suppression might ameliorate the 
negative effects of reduced Tbx1 dosage because it suppresses self renewal and promotes 
differentiation of stem cells (Jain, Allton et al. 2012; Meletis, Wirta et at 2006). In addition, 
because Cdkn1a is negatively regulated by Tbx1 and positively regulated by p53, reduced 
dosage of the latter protein may buffer the effect of Tbx1 on Cdkn 1 a expression. 
We crossed Trp53+1- and Tbx1+1- mice and harvested embryos at E10.5 in order to test 
whether there is a genetic interaction between Tbx1 and Trp53, and to check if suppression 
of p53 is sufficient to rescue or ameliorate defects observed in Tbx1+1- mutant embryos, and 
test its effects on the typical haploinsufficiency phenotype, i.e. hypoplasia or aplasia of the 
4th pharyngeal arch arteries (4th PAAs) (Jerome and Papaioannou 2001; Lindsay, Vitelli et 
al. 2001; Merscher, Funke et al. 2001). We analyzed, by intracardiac ink injection, a total of 
56 embryos and the results are summarized on Tab. 1A. 
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A 
Genotype (E10.5) I Normal 4th PAA defects 
Tbx1 +'+ 
--I--- ---- -- -
16 0 
Tbx1 +,. 1 12 (92%) 
Trp53+[' ; Tbx1 +" - f- -- -10 1 (9%) * 
--- -
Trp53+" 16 0 
* P=O.00004 
B 
Genotype (E10.5) I Pifithrin-a Normal 1 4th PAA defects 
I 
• - -- -- - .-Untreated 10 0 
Tbx1 +,+ --Treated 7 0 
- ~- -
Untreated 0 10 (100%) 
Tbx1 +/. -Treated 14 5 (36%) * 
* P=O.00016 
Table 1: Rescue of fourth pharyngeal arch artery defects by genetic or pharmacological 
suppression of p53. (A) Genetic experiment. (8) Treatment with Pifithrin-Ct. 
PM: pharyngeal arch artery. "Normal" refers to the pattern of the PM system. 
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WT and Trp53+
'
- embryos were all normal (n=32) while Tbx1+1- where mostly abnormal (12 
out of 13 embryos or 92%)_ Double heterozygous Trp53+/-;Tbx1+/- embryos , however, were 
mostly normal (10 out of 11 embryos, or 91 %, P=0.00004) . Examples of ink injection data are 
shown on Fig. 18. As shown , in WT embryos (Fig . 18A) all three PMs (the 3rd , the 4th and 
the 6th) are developed, in Tbx1+1- embryos (Fig. 188) there is aplasia of the 4th PM, that is 
rescued in Trp53+/-;Tbx1+/- embryos (Fig. 18C). Therefore , Trp53 deletion almost completely 
rescues this particular phenotype. 
Figure 18: Trp53 deletion rescues the 4th PAA defects in Tbx1 +/- embryos. 
Examples of ink injections assays for the visualization of the pharyngeal arch arteries in 
E10.5 embryos. (A) Ink-injected , WT E10.5 embryo showing the normal anatomy of the 3rd , 
4th and 6th pharyngeal arch arteries on the left. (8) Ink-injected, Tbx 1 +/ -; Trp53+/+ E10.5 
embryo . Note the absence of the left 4th PM. (C) Ink-injected , Tbx 1 +/-; Trp53+/- E10.5 
embryo. Note the presence and normal anatomy of the 4th PM. 
Arrowheads indicate the 4th PM. 
4.3 p53 transient pharmacological inhibition rescues the Tbx1 haploinsufficiency 
phenotype 
To exclude that in Trp53+/-;Tbxr/- embryos, Tbx1 haploinsufficiency phenotype 
rescue was due to a gene mutation linked to the mutant Trp53 allele or to genetic 
background , we used an alternative approach to inhibit Trp53 , therefore we repeated the 
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experiment using pharmacological suppression of pS3 with a specific inhibitor of p53, 
Pifithrin-a, (Komarov, Komarova et al. 1999) and the effect of this drug was examined. 
Timing of drug administration to pregnant females was based upon our previous findings 
showing that Tbx1 is required for 4th PM development as early as E7.S but it is not longer 
required after E9.S (Xu, Cerrato et al. 200S). Therefore, we injected Pifithrin-a into pregnant 
females at E7.S, E8.S and E9.5, and harvested embryos at E10.5 to score the 4th PM 
phenotype. Results (Tab. 1 B) showed again a significant suppression of the 4th PM defect 
(P=O.00016). Thus, reduced dosage of pS3, either provided by permanent deletion of the 
gene or by temporary restricted pharmacological inhibition, has a significant suppressing 
effect upon the Tbx1 haploinsufficiency phenotype. 
4.4 Trp53 mutation modifies the hypomorphic but not the null Tbx1 phenotype. 
Reduced p53 dosage may suppress the Tbx1 mutant phenotype indirectly, e.g. 
through a compensatory mechanism that buffers the consequences of loss of Tbx1, or it may 
act more specifically by interacting with the normal transcriptional functions of Tbx1. While 
these hypotheses are not mutually exclusive. if the second mechanism is significant. the 
Tbx1 protein must be present for the rescue to occur. Therefore. we first tested whether 
Trp53 mutation can modify the intracardiac phenotype of Tbx1"'- embryos. To this end. we 
crossed Tbx 1 +1-; Trp53+1- and Tbx1+1-; Trp53+1+ mice and harvested embryos at E18.5. when 
the cardiac phenotype can be fully assessed morphologically. Results. summarized on Fig. 
19A. confirmed the rescue of the haplolnsufficiency phenotype also at this developmental 
stage. but revealed that Tbx1"'-; Trp53+1+ and Tbx1"'-; Trp53+1- embryos were phenotyplca"y 
indistinguishable (Fig. 19) presented with TAC. that communicates exclusively with the right 
ventricle. and VSD. 
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A Genotype E18.5 
Tbx1 Trp53 Normal CV defects 
+1+ +1+ 13 0 
+1+ +/- 9 0 
+/- +/+ 5 11 (a) 
+/- +/- 19' 3 (a) 
-1- +1+ 0 10 (b) 
-/- +/- 0 6 (b) 
, 0.00051 
B B' 
T T 
"). 
-,-
>< ~ • 
LV LV 
C C' 
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RV 
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Figure 19: Trp53 ablation in a Tbx1 null background causes severe cardiovascular 
abnormalities as in Tbx1-1- embryos, (A) Tabulated summary of card iovascular phenotype 
in E18.5 Tbx1 mutants with and without Trp53 deletion. Normal : refers to heart phenotype ; 
CV defects: refers to card iovascular defects observed in Tbx1 +/- and Tbx1 -/- embryos . 
Rescue of the aortic arch haploinsufficiency phenotype was confirmed at E18.5 (asterisk). 
(B-C') Histological section of E15.5 embryo hearts showing essentially the same phenotype 
with or without Trp53 ablation . (8-8 ') Two different sections of the same heart of a Tbx1 -1-
embryo, showing truncus arteriosus communis (T) communicating with the right ventricle and 
ventricular septal defects (arrowhead ). (C-C') Two different sections of the same heart of a 
Tbx 1-1-; Trp53+/- embryo showing the same phenotype an in Tbx1 null embryo. 
T: truncus arteriosus communis; RV: right ventricle ; LV : left ventricle . 
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Next, we used the hypomorphic allele Tbx1 neo2, which expresses approximately 15% of the 
Tbx1 mRNA compared to the WT allele (Zhang and Baldini 2008). We crossed Tbx 1 +1-
;Trp53+1. and Tbxrlneo2;Trp53+1+ mice and harvested embryos at E18.5. A tabulated 
summary of cardiac phenotyping data is shown in Fig . 20A. The external appearance of 
Tbx1 -1neo2;Trp53+1+ and Tbx1 ..fneo2;Trp53+1. embryos was indistinguishable and embryo 
dissection showed that both genotypes had absence or severely hypoplastic thymus . 
However, cardiac phenotyping revealed some important differences. Most notably, 3 of the 
18 Tbx1 ..fneo2;Trp53+1. embryos examined (17%) showed a normally septated heart (Fig. 20B-
C'), while all the 17 Tbx1 ..fneo2;Trp53+1+ embryos examined had a complex septation defect 
(see for examples Fig . 21 panels A, S, E, F). 
A Genotype n Normal VSD DORV Incomplele TA 
(E1 8 5) TA 
Tbx 1..Noo· 17 0 0 13 
Trp53·". Tbxl '-" 18 1 6 + 2(ovAo) 4. l(ovTA) 
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Figure 20: Trp53 deletion ameliorates the outflow tract phenotype in Tbx1 hypomorphic 
mutants. (A) Tabulated summary of cardiovascular phenotype in hypomorphic mutants with 
and without Trp53 deletion. 
n: total number of embryos examined with the genotype indicated . Normal : refers to heart 
phenotype ; VSD: ventricular septal defects ; DORV: double outlet right ventricle ; TA: Truncus 
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arteriosus communis; ovAo: overriding aorta; ovTA: overriding of (unseptated) truncus 
arteriosus. 
Histological sections of E18.5 embryo hearts showing complete rescue of ventricular and 
conotruncal septation. (B-B') Two different sections of the same heart of a WT littermate of 
the embryo shown in C-C'. (C-C') Two different sections of the same heart of a Tbx1' 
1n«J2;Trp53+1• embryo. Note the normal septation of the great arteries and ventricles, similar to 
WTembryos. 
A: Aorta; P: Pulmonary trunk; RV: right ventricle; LV: left ventricle. 
In addition, 3 Tbx1-1neo2;Trp53+/' embryos presented with a milder form of double outlet right 
ventricle (DORV) or incomplete truncus arteriosus (TA). In these cases, the aorta or the 
truncus arteriosus were overriding the ventricular septum, while in Tbx1.fneo2;Trp53+1+ 
embryos they originated from the right ventricle (Fig. 21). This indicates that Trp53 mutation 
improves the alignment between the outflow tract and the ventricles. Furthermore, we found 
a single case of isolated VSD among the Tbx1-1neo2;Trp53+" embryos (Fig. 21 F-H). In contrast, 
all of the Tbx1-1neo2;Trp53+1+ embryos examined presented with VSD associated with 
conotruncal septation defects or DORV (Fig. 20A). 
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Figure 21 : Trp53 deletion ameliorates the outflow tract phenotype in Tbx1 hypomorphic 
mutants at E18.5. (A-A') Two sections of the same heart of a Tbx1 -1neo2;Trp53+1+ embryo. 
Note that both the aorta and the pulmonary trunk originate from the right ventricle. This is an 
arrangement observed in all the embryos with this genotype. (B-B'-C) Three sections of the 
same heart of a Tbx1 -1neo2;Trp53+1- embryo. The pulmonary trunk communicates with the right 
ventricle , while the aorta communicates with both ventricles, indicating a better alignment 
between the outflow and the heart chambers, compared with the embryo shown in A-A' . 
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In C, the section is shown at a lower magnification to fit the panel. (0-0') Two sections of the 
same heart of a Tbx1-1neo2;Trp53+1+ embryo. Note that the truncus arteriosus communis (T) is 
positioned directly above the RV. (E-E') Two sections of the same heart of a Tbx1-
1neo2;Trp53+1- embryo. The truncus arteriosus communis communicates with both the RV and 
LV, above the interventricular septum. (F-G-H) Three sections of the same heart of a Tbx1-
1neo2;Trp53+1- embryo. The pulmonary trunk is connected to the RV and the aorta to the LV. 
Although the latter is located above the septum, it does not directly communicate with the 
RV. 
In H, the section is shown at a lower magnification to fit the panel. 
OORV: Double outlet right ventricle; Inc. TA: incomplete truncus arteriosus (there is truncal 
septation but not conal septation). VSO: ventricular septal defect. A: Aorta; P: Pulmonary 
trunk; T: truncus arteriosus (unseptated); RV: right ventricle; LV: left ventricle. Arrowhead: 
interventricular communication (VSO). 
4.5 Trp53 ablation rescues the proliferation defect In a Tbx1-1n«1Z background 
It has been demonstrated that Tbx1 ceil-autonomously maintains the cardiac 
progenitor population within the SHF by enhancing the prOliferation of cardiac precursor 
cells. Cell proliferation and apoptosis analysis in mesodermal speCific conditional Tbx1 
mutants revealed an obvious reduction of mitotic cell number in the splanchnic mesoderm, 
by contrast, no changes in apoptotic activity was observed (Zhang, Huynh et al. 2006). 
Because the OFT phenotype of Tbx1 mutants is associated with reduced cell proliferation in 
the SHF, we tested whether Trp53 ablation can rescue the proliferation defect in a Tbx1-1neo2 
background, thus providing a possible explanation of the partial rescue of the OFT 
phenotype. To this end, we immunostained histological sections of WT, Tbx1-1neo2;Trp53+1+ 
and Tbx1-1neo2;Trp53+1• E9.5 embryos with an anti phosphorylated histone 3 (PH3) antibody 
and evaluated the percentage of PH3+ cells in the SHF area (operatively defined as the 
posterior pericardial wall excluding inflow and outflow proper) (Fig. 22). Results showed that 
65.1 % of the SHF cells were PH3+ in WT embryos, 43.5% in Tbx1-1neo2;Trp53+1+ embryos, 
confirming the reduction of cardiac precursors in Tbx1 hypomorphic mutants, and 53.3% in 
Tbx1-1No2 ;Trp53+1• , Significantly more than in Tbx1-1neo2;Trp53+1+ littermates (P«0.001). Thus, 
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Trp53 ablation had a significant impact on SHF cell proliferation in a Tbx1 mutant 
background . 
C Genotype (E9.5) MI (%) 
Tbx1-' -;Tp53-' -
n=3 
(2000ceIlSigenotype) 65 
Tbx1 002 
n=3 
(200OceIlSigenotype) 43 
M Tbx1.fNeol;Tp53+1• LO 
~ n=3 53 
. ~ .. 
(2000ceIlSigenotype) 
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Figure 22 : Trp53 ablation rescues cardiac precursors proliferation defects in Tbx1·lneo2 
background. (A, B) E9.S. sagittal sections immunostained with an anti-phospho-Histone H3 
antibody to evaluate cell proliferation; the area where cell proliferation quantification were 
performed is indicated by the red boxes . (C) Mitotic index (M.I.) in the SHF area at E9.S 
mutant embryos . P values were calculated using the Chi-squared test. 
I PA: first pharyngeal arch ; OFT: outflow tract; SHF: second heart field ; H: heart. 
4.6 Tbx1 and p53 proteins co-occupy chromatin segments. 
To gain insights into the nature of the Tbx1-pS3 interaction, we first tested whether 
p53 and Tbx1 regulate each other (Fig . 23A-B). We analyzed Tbx1 and Trp53 expression in 
WT, Tbxrl ., Trp53+1. and double heterozygous Trp53+1.; Tbx 1 +1· E8.5 embryos. Results 
excluded that Trp53 is a negative regulator of Tbx1 expression in mouse embryos , and vice-
versa . Next, we tested whether the two proteins interact directly. However, co-
immunoprecipitation did not reveal any interaction (Fig. 23C). Next, we asked whether the 
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two proteins , albeit not interacting directly, occupy the same chromatin regions . To this end, 
we used chromatin immunoprecipitation combined with western blotting (ChIP-WB). 
Chromatin was extracted from cross-linked differentiated P19CI6 cells, fragmented to a 
range of 150-350 bp and immunoprecipitated using anti-Tbx1 or anti-p53 antibodies . 
Captured complexes were released , de-cross-linked , and proteins were subjected to western 
blot analyses . Results showed that the p53 protein was present in the Tbx1-captured 
complexes (Fig. 230), and vice-versa (Fig. 23E). Thus, there are chromatin segments that 
are occupied by both Tbx1 and p53 , suggesting that the two transcription factors co-regulate 
shared targets . 
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Figure 23: Molecular analyses of Trp53-Tbx1 interaction. (A-B) Quantitative real time PCR 
evaluation of Tbx1 and Trp53 expression in E8.5 embryos with the genotypes indicated. 
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Tbx1 expression is associated with heterozygous deletion, as expected, but is not affected 
by the presence of Trp53 deletion. Similarly, Trp53 expression is halved in Trp53+1• embryos, 
as expected, but is not affected by the presence of Tbx1 deletion ***: P=0.001. Error bars 
indicate standard error of the mean (SEM) of five independent experiments. (e) 
Immunoprecipitation experiment using nuclear extracts from differentiated (4Bhrs) P1gel6 
cells and an antibody anti Tbx1. In parallel we used also cells transfected with a Trp53 
expression vector (lane 2 and lane 4). We carried out western blotting using an antibody 
against p53 and Smarcd1/BafSOa (positive control). The p53 protein is not co-
immunoprecipitated. (0) ChiP-western blot experiment using an anti Tbx1 antibody. The p53 
protein is readily detected. (E) ChiP-western blot experiment using an anti p53 antibody. The 
Tbx1 protein is present in the eluate. 
4.7 The Gbx2 gene Is down regulated In Tbx1+1- embryos and rescued by Trp53 
mutation 
To identify putative shared targets, we followed a candidate gene approach. We 
considered three Tbx1 target genes that are known to interact with Tbx1 during 4th PM 
development, WntSs, Smad7 and Gbx2 (Chen, Fulcoli et al. 2012; Papangeli and Scambler 
2013; Calmont, Ivins et al. 2009). We first tested the expression of these genes in WT, 
Tbx1+", Trp53+", and Tbx1+"; Trp53+" EB.5 embryos using quantitative reverse transcription 
peR (qRT-PCR). Results showed Gbx2 to be the most interesting target because its 
expression was the most affected by heterozygous Tbx1 deletion (Fig. 24A-C). Both Gbx2 
and Tbx1 are strongly expressed In the pharyngeal region of EB.5 embryos (Fig. 240,E). 
Section analysis showed that Gbx2 Is expressed predominantly in the pharyngeal surface 
ectoderm (PSE), although some staining could also be detected in the pharyngeal 
endodermal (P.endo) layer (Fig. 240',E'). Therefore, Tbx1 and Gbx2 show overlapping 
expression domains at the time of 4th PM speCification. Gbx2 expression in Tbxf" embryos 
at EB.5 was lost from both the PSE and the P .endo, and when Gbx2 expression was 
examined In Tbx1 PSE conditional mutants, its expression was lost in the PSE, whereas it 
was maintained in the P.endo (compare Fig. 24G with 24H, and Fig. 24A' with 24H'). 
Therefore, decreased Gbx2 expression is more likely to be due to gene dowregulation than 
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to a lack of development/survival of Gbx2 expressing cells in the PSE. Thus, it has been 
demonstrated that Gbx2 expression was lost in some regions of E8.5 Tbx1 null embryos 
(Calmont, Ivins et al. 2009), but differential expression of Gbx2 was never seen in Tbx1+/' 
mutants. 
Our qRT -PCR analysis on E8.5 embryos showed these results; Gbx2 expression was 
reduced in Tbx1+/- mutants, but it was not affected by Trp53 deletion and, strikingly, 
expression returned to WT levels in Tbx1+1-;Trp53+1- embryos (Fig. 24C). Homozygous 
deletion of Gbx2 causes similar 4th PM abnormalities to those in Tbx1+1- embryos, and Gbx2 
heterozygous deletion strongly enhances the Tbx1 haploinsufficiency phenotype (Calmont, 
Ivins et al. 2009). Therefore, it is likely that at least part of the gene haploinsufficiency rescue 
in Tbx1+1-; Trp53+'- embryos is due to rescue of Gbx2 expression. 
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Figure 24: Trp53 deletion rescues the Gbx2 expression down regulation in Tbx1+lo EB.5 
embryos. (A-B) Quantitative real time PCR (qPCR) evaluation of the Smad7 (A) and Wnt5a 
(8) gene expression in E8.5 embryos (2 embryos/genotype). None of the variation observed 
are statistically significant. (C) qPCR evaluation of the Gbx2 gene expression in E8.5 
embryos (5 embryos/genotype). The expression is significantly reduced in Tbx1+lo embryos 
and significantly enhanced in double heterozygous embryos. There is not significant 
difference between WT and double heterozygous embryos. **: P= 0.004. Error bars indicate 
SEM of five independent experiments. (D-H') In situ hybridization (ISH) for Gbx2 on WT 
embryos (0-0 ', G), Tbx1"lo embryos (F, F'), Tbx1-PSE (AP2aCrel+;Tbx1 fl0x!f10X) embryos (H , H') 
and ~-galactosidase staining of Tbx1 +lo embryos (E , E'). Dotted lines in 0 , E, F, H show 
section plane in 0 ', E', F' , H', respectively. Red and yellow arrows indicate regions of Gbx2 
and Tbx1 staining in the PSE and in the P.endo, respectively . Black arrowhead indicates 
Tbx1 expression in the head mesoderm ; blue arrowhead indicates Tbx1 in the SHF 
mesoderm (Calmont, Ivins et al. 2009). 
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4.8 A DNA fragment adjacent to the Gbx2 gene Is occupied by both Tbx1 and p53 
transcription factors 
Our results demonstrated that Trp53 ablation rescues Gbx2 expression in vivo. In vitro 
experiments demonstrated that Tbx1 and pS3 could be part of the same chromatin complex. 
Therefore, based on these evidences, we asked whether the Gbx2 gene may be occupied by 
both Tbx1 and pS3 proteins, explaining the regulation of Gbx2 expression either after Tbx1 
haploinsufficiency or after Trp53 ablation in a Tbx1+'o background. To this end, we 
computationally searched for T-box binding elements (TBEs) and pS3 binding elements 
(pS3BEs). 
No direct Tbx1 binding sites have been identified so far, anyway Agarwal and colleagues 
(Agarwal, Wylie et al. 2003) have shown in vivo that Fgf10 requires TbxS for initiation of its 
expression. This is supported by their In vitro transactivation data, which show powerful 
activation of the Fgf10 promoter by TBXS, through an evolutionary conserved T-box binding 
element (TBE) located in the S' region of the Fgf10 gene. It has been demonstrated that 
Tbx1 can directly activate the Fgf10 promoter through that TBE in a tissue culture assay (Xu 
H. et al., 2004), raising the intriguing possibility that different T -box transcription factors may 
share target genes. So we used the TbxS consensus DNA sequence, loosely defined as 
AlGITG/AGTGNNA using a position weight matrix (PWM) based on all published T -box 
binding sites, to look for evolutionary conserved T-box binding elements into the Gbx2 gene. 
The rVlSTA program was used to align Gbx2 and 3kb of upstream and downstream human 
and mouse genomic regions, In order to search putative TBEs and pS3BEs. From this 
computational analysis we found 4 candidate sites for each of these transcription factors 
(Fig. 2SA). The 4 TBEs were found in the downstream region of the Gbx2 gene, while of the 
4 pS3BEs, 2 were found In the upstream region and other 2 are positioned in the 
downstream region of the Gbx2 gene. Moreover, more recently, in our laboratory a genome-
wide ChiP-seq assay has carried out to map binding sites of Tbx1. Results have shown Tbx1 
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enrichment in the downstream region of the Gbx2 gene, therefore we focused on th is region 
to test a direct bind of Tbx1 to the gene. 
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Figure 25: p53 and Tbx1 occupy a DNA segment adjacent to the Gbx2 gene. (A) Left: 
schematic representation of the Gbx2 gene showing the position of computationally-detected 
T-box (blue) and p53 (red) binding sites. Right: summary of results of ChiP experiments. +: 
enriched; -: not enriched; NT: not tested. The genomic coordinates (mm10) of T8E4 and 
p538E3 are chr1 :89925759-89925824 and chr1 :89927115-89927206, respectively. (8) 
Quantitative ChiP results for the two enriched sites. Left: ChiP using an anti Tbx1 antibody; 
Right: ChiP using an anti p53 antibody. *: P=0.04 **: P= 0.009. Error bars indicate mean ± 
standard deviation of 4 independent experiments. (C) Quantitative ChiP with an anti 
H3K27me3 antibody at the p538E3 site. The experiment was carried out from P19CL6 
transfected with a control siRNA (NT) or with an anti-p53 siRNA (p53KO). The 
immunoprecipitation was carried out with an anti Trimethyl-Histone H3 (Lys27) antibody. 
Note that the level of H3K27me3 at the p538E3 site is Significantly lower in the p53 knock 
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down sample . • : P= 0.05 . Error bars indicate mean ± standard deviation of 2 independent 
experiments. 
To test whether these TBEs and p53BEs are occupied by each of the transcription factors , 
we performed ChiP of cardiomyocyte differentiated P19CI6 cells (48 hrs. after induction of 
differentiation). We chose th is in vitro system because under these conditions all three 
endogenous genes (Tbx1, Trp53 and Gbx2) are expressed and , interestingly, Gbx2 gene is 
not expressed in undifferentiated P19CL6 cells , its expression starts after induction of 
differentiation , reaching its maximal expression at day 2 and day 3 of differentiation (Fig . 26). 
A 
+5AZA 
TO 
B 
30 
C 25 
0 
cJ) 20 
<L> cJ) 
> Q) 
. _ L-
+Jo... 
ro X 15 
<L> Q) 
n::« 10 
z 
n:: 5 
0 
+DMSO 
I 
T1 
Gbx2 
TO T1 T2 
+ DMSO 
,+. 
T2 
T3 
2 
DMSO treatment 
until beating. 
==> Collected at day 2 
for ChiP assays 
T4 T5 T6 
Figure 26: Gbx2 expression during cardlomyocyte differentiation of P19CL6 cells. (A) 
Schematic representation of cardiomyocyte differentiation of P19CL6 cells. (B) qRT -PCR 
results showed the maximal Gbx2 expression at day 2-3 of differentiation. 
Quantitative ChiP using an anti-Tbx1 antibody revealed the occupation of TBE4 (Fig. 25B, 
left panel). while ChiP with an anti-p53 antibody revealed occupation of p53BE3 (Fig. 25B, 
right panel), in four independent experiments per antibody. 
The gene expression data shown above suggest that p53 alone does not have a 
direct effect on Gbx2 expression, but its deletion buffers the effect of the Tbx1 deletion. 
Therefore, considering that p53 has been shown to interact with a component of the 
Polycomb repressive complex 2 (Yang, Wang et a!. 2013), we asked whether p53 
suppression may alter the chromatin state of the Gbx2 genetic element occupied by p53 and 
Tbx1. To this end, we knocked down Trp53 during differentiation of P19CL6 cells (Fig. 27), 
and we performed qChlP (48 hrs. after induction of differentiation) with an anti H3K27me3 
antibody and found that the DNA segment is highly enriched for this histone modification, but 
after p53 suppression by siRNA, the levels of H3K27me3 are substantially reduced (Fig. 
25C). 
Overall, these results indicate that Gbx2 is regulated by both transcription factors. 
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Figure 27: Trp53 knockdown during cardiomyocyte differentiation of P19CL6 cells. (A) 
Schematic representation of siRNA transfection during differentiation of P19CL6 cells. (8) 
80% reduction of mRNA (left panel) and reduction of the protein (right panel) was achieved 
after 48 hrs from transfection . 
4.9 The DNA fragment occupied by Tbx1 and p53 is sensitive to p53 dosage in a 
luciferase reporter assay 
Gene expression analysis showed that Gbx2 expression is restored in Tbx1 +1- E8.5 embryos 
after ablation of Trp53 , but its expression is not modified in Trp53+1- embryos, and ChiP 
experiments demonstrated that p53 binds to Gbx2. To understand whether the identified site 
bound by p53 is really negatively regulated by this transcription factor, we cloned an 
evolutionarily conserved (in human and mouse) DNA segment containing the p53BE 
identified by ChiP analysis, into a luciferase reporter plasmid with a basic promoter (Fig. 
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28A). We then carried out luciferase assays on human JEG3 choriocarcinoma cells 
transfected with increasing amount of a Trp53 expression vector together with equal amount 
of the luciferase reporter construct. Due to the quite strong activity of the basal promoter in 
the construct, the basal luciferase activity was not too low to appreciate a decrease in the 
presence of p53. Results showed that the DNA segment responded well to transfected p53. 
Increasing amount of the p53 protein results in a reduction of the relative luciferase activity 
compared to the control, in a dose dependent manner (Fig. 288). Thus, our results showed 
that this p53BE is required for p53-induced inactivation in this assay. 
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Figure 28: Gbx2 has a conserved p53 binding element (p53BE) that is required for 
response to p53 in luciferase assays. (A) Schematic illustration of the luciferase reporter 
construct containing a Gbx2 DNA fragment with a TBE and a p53BE. (B) Luciferase assays 
on transfected human JEG3 cells . Gbx2 luciferase reporter activity is sensitive to p53 
dosage. Error bars ind icate standard error of the mean (SEM ) of six independent 
experiments. 
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CHAPTER 5 - DISCUSSION 
Gene haploinsufficiency is a situation in which a single functional copy of a gene, in a 
diploid organism, is insufficient to support a normal phenotype. Loss of a functional copy of a 
gene may be due to a chromosomal deletion, a mutation that causes loss of the RNA 
message or of its stability, or that causes an altered, non functional protein product. Gene 
haploinsufficiency is transmited as a dominant trait. Most genes are not haploinsufficient, 
therefore, a loss-of-function allele often has no discernible phenotype. This phenomenon has 
been attributed to the metabolic theory of dominance described over 30 years ago. Briefly, 
this model states that the phenotypic consequences of heterozygous loss-of-function alleles 
are masked by the presence of one wild-type allele due to the redundancy of cellular 
physiology (Kaeser and Burns, 1981). There are, however, exceptions to this rule where 
deletion of a single gene copy leads to an abnormal phenotype. Such haploinsufficiency is 
observed in all eukaryotes from yeast to humans. The relevance of haploinsufficiency in 
human disease has become Increasingly apparent. Many of the haploinsufficient mutations in 
humans are observed in transcription factors, and it is not surprising that such 
haploinsufficlencies are detrimental, as they should result in multiple transcription defects of 
diverse downstream targets (reviewed in Seidman and Seidman, 2002). Haploinsufficiency 
has also been Implicated in cancer; heterozygous mutations in both Trp53 (Venkatachalam, 
Stuart et ai., 2001) and A TM (Spring, Ahangari et ai., 2002) result in increased cancer 
susceptibility . 
Gene haplolnsufficlency is often a cause of genetiC disease and indicates absence or 
insufficiency of genetiC buffering system(s) to compensate for the loss of one copy of the 
gene. Comparison of known haploinsufflcient Vs. haplosufficient genes indicated that 
haploinsufflclent genes tend to have, I) developmental or morphogenetic importance, Ii) more 
interactions with other genes and iii) interact with other haploinsufficient genes (Huang, Lee 
et al. 2010). 
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Hemizygous deletion of 22q11 affects approximately 1 :4000 live births and may give rise to 
many different malformations but classically results in a constellation of phenotypes that 
receive a diagnosis of DiGeorge syndrome, velocardiofacial syndrome, or, now more 
commonly, 22q11.2 deletion syndrome (22q11.2DS). Particularly affected are the heart and 
great vessels, the endocrine glands of the neck, the face, the soft palate, and cognitive 
development. Although up to 30 genes may be deleted, it is haploinsufficiency of the 
transcription factor TBX1 that is thought to make the greatest contribution to the disorder. 
Chromosome engineering, transgenic complementation, and gene targeting experiments 
revealed that haploinsufficiency of the T -box transcription factor Tbx1 produces a partial 
phenocopy of the syndrome. Mouse embryos are exquisitely sensitive to varying levels of 
Tbx1 mRNA; thus Tbx1 is a dosage-sensitive gene, and its haploinsufficiency affects a 
number of morphogenetic and developmental processes. Tbx1 gene, when haploid results in 
fourth PAA abnormalities, while loss of function of Tbx1, as tested in Tbx1-1- embryos, leads 
to disruption of PAAs 3-6, possibly secondary to lack of segmentation of the distal 
pharyngeal arches and pouches. Great artery defects involving third and sixth PAA 
derivatives are almost never seen in 22q11.2DS patients, suggesting that the 
haploinsufficiency model reflects more closely the aortic arch defects than do the 
homozygous mutations. Phenotypic anomalies also extend into adult life, patients reaching 
adolescence and adulthood have a predisposition to neuropsychiatric disease, for which 
there is no speCific treatment. Thus, understanding gene haploinsufficiency mechanisms is 
not only important from a biological point of view, but it is also potentially important for the 
development of future treatments. 
In this work I searched for genetic and pharmacological strategies to rescue the Tbx1 
mutant phenotype and I considered cell proliferation as a potential target. It is known that 
Tbx1 has a positive role to control cell proliferation in different cell types and through different 
pathways (Vitelli et at, 2003; Vitelli, Lania et at 2010; Fulcoli, Huynh et at 2009). From in 
vitro studies I found that Tbx1 enhanced cell prOliferation and this effect could be a 
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consequence of down-regulation of two cell cycle inhibitors, Cdkn 1 a and Cdkn 1 b. It has been 
demonstrated that Cdkn1a expression is up-regulated in Tbx1-1- mouse dental epithelium 
(Cao, Florez et al. 2010) and it has been proposed that this up-regulation is due to the 
interaction of Tbx1 with the C-terminal tail of PITX2, leading to inhibition of PITX2 
transcriptional activation of Cdkn1a promoter. Thus, proposing a new mechanism by which 
Tbx1 promotes cell proliferation. Therefore, one possibility is that Cdkn1a down-regulation by 
Tbx1 could be done by inhibition of p53-dependent transcriptional activation of this gene. 
Using program rVista, I searched for TBEs within the Cdkn1a promoter, near two p53BEs 
known to be responsible for Cdkn 1 a transcriptional activation (Laptenko, Beckerman et aI., 
2011). I found 2 TBEs, but none was occupied by Tbx1, as determined by ChiP assay in my 
tissue culture model (P19CL6). However, another possibility is that Cdkn1a activation by p53 
requires the binding of cofactors, such as a component of the SWIISNF chromatin 
remodeling complex, Baf60a (Oh, Sohn et aI., 2008). This protein interacts with both Tbx1 
(Chen, Fulcoli et al. 2012) and p53 (Oh, Sohn et aI., 2008), therefore it is possible that Tbx1 
and p53 proteins compete with each other in binding to Baf60a, and if there is a relative 
excess of Tbx1, there may be less Baf60a available for p53, leading to reduced activation of 
Cdkn1a expression. 
Thus, Tbx1 may be faCilitating cell proliferation through negative regulation (direct or indirect) 
of cell cycle Inhibitors. 
In this work, I followed a rationale that was based on the contrasting effects of Tbx1 
and a Cdkn1a-Cdkn1b activator, p53, on cell differentiation and proliferation, for devising a 
genetiC and pharmacological rescue strategy. First of all I focused my study on the Tbx1 
haploinsufflciency phenotype. Of particular note, heterozygotes show 4th PAAs hypo/aplasia, 
hypoplasia of the parathyroid and thyroid glands and behavioral abnormalities. The detection 
of the 4th PAA hypo/aplasia was very important, because normal growth and remodeling of 
this structure is necessary for final patterning of the mature aortic arch, and its loss causes 
the interruption observed in IAA-B. The penetrance of 4th PAA and other defects is greatly 
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affected by genetic background (Taddei, Morishima, et al. 2001). The genetic background 
affects the extent of "recovery" of arterial growth of the 4th PAA during development (Lindsay 
and Baldini, 2001) as well as the penetrance of initial abnormalities. I found that Trp53 
heterozygous deletion was effective in rescuing the Tbx1 haploinsufficient phenotype in early 
embryos, during the formation of the arteries, as demonstrated by the analysis of the 4th 
PAA phenotype in E10.5 mutant embryos. Analysis of the 4th PAAs derivatives in E18.5 
embryos, confirmed the rescue of the haploinsufficiency phenotype also at this 
developmental stage. I excluded that rescue is due to regulation of Tbx1 gene expression by 
p53 because Trp53 deletion does not affect Tbx1 expression in embryos. Similarly, I 
excluded that rescue is due to regulation of Trp53 gene expression by Tbx1 because, also in 
this case, Tbx1 heterozygous deletion does not affect Trp53 expression in embryos as well 
as in tissue culture systems. It is also unlikely that rescue may be due to the anti-apoptotic 
effects of loss of p53. Indeed, abnormal apoptosis is not part of the Tbx1 mutant phenotype 
(Vitelli, Morishlma et al. 2002; Calmont, Ivins et al. 2009). I propose an alternative 
explanation, I speculate that Tbx1 and p53 cooperate in regulating specific targets relevant 
for the development of the structures rescued by Trp53 mutation. This view is supported by 
the specificity of rescue and by the co-immunoprecipitation of p53 and Tbx1 in ChiP assays. 
Indeed, the gene Gbx2, encoding a homeobox protein required for normal development of 
the 4th PAAs, is occupied by both Tbx1 and p53 and its expression is affected by Tbx1 
heterozygosity, but not by Trp53 heterozygosity, and it is rescued by combined mutation of 
Tbx1 and Trp53. Gbx2 and Tbx1 are co-expressed in the pharyngeal surface ectoderm and 
in the pharyngeal endoderm (Calmont, Ivins et al. 2009), tissues that have been linked to the 
4th PAA phenotype (Zhang, Cerrato et al. 2005; Calmont, Ivins et al. 2009; Randall, McCue 
et al. 2009). Gbx2 haplolnsufficiency alone shows normal PAAs development, while Gbx2 
haplolnsufficiency In a Tbx1 heterozygous background enhances the 4th PAA phenotype in 
Tbx1 mutants. 
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Therefore, Gbx2 is a strong candidate for being a shared target, and the rescue of its 
expression in double mutants could explain the rescue of the 4th PAA phenotype. 
Then, I focused my study on the Tbx1 null phenotype. Homozygous null mutation of 
Tbx1 causes more severe defects including failure of the outflow tract (OFT) septation, and 
absence of the caudal pharyngeal arches. Tbx1 is a transcriptional modulator, and 
deregulation of this activity has been linked to alterations in the expression of various genes 
involved In cardiovascular morphogenesis. OFT septation requires Tbx1 between E8.5 and 
E9.5. Using a Tbx1mctn (tamoxifen-inducible Cre knocked into the Tbx1 locus), it has been 
shown that induction of Cre activity at E8.5 reveals contribution to the OFT endothelium and 
myocardium of cells derived from Tbx1-expresslng progenitors (Xu, Cerrato et aI., 2005). 
Tbx1 is required in all three germ layers of the embryonic pharyngeal region for normal 
development. Mesp1Cre was used to ablate Tbx1 activity in mesodermal derivatives. By late 
gestation, mesodermal mutants strongly resembled Tbx1"'- embryos, with severe thymic 
defects, persistent truncus arteriosus, VSDs, and aortic arch defects as well as hypoplastiC 
ears. At E10.5, the conditional mutants had lost the 2nd, 4th and 6th branchial arches, and 
had hypoplastic second arches, again reminiscent of Tbx1 nulls (Zhang, Huynh et aI., 2006). 
These data suggest that mesodermal expression of Tbx1 has a critical role in pharyngeal 
segmentation. Loss of the arch arteries in mesodermal mutants might be explained by the 
lack of the arches themselves. The OFT phenotype observed in Tbx1"'- mutants are 
associated with decreased cardiac precursors proliferation and their premature 
differentiation, and It has been reported that Tbx1 controls cell proliferation and affects 
cellular differentiation in a cell autonomous fashion, but it also directs non-cell autonomous 
effects (Vitelli, Morishima et al., 2002) 
As I mentioned above, the mouse embryo is sensitive to Tbx1 expression level. Intronic 
Insertion of a selection cassette has been used to generate hypomorphic alleles of Tbx1 
(Zhang and Baldini, 2008). Systematic analysis of the phenotype associated with a 
hypomorphic series revealed differing sensitivities to reduced Tbx1 dosage in different 
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organs and structures. PAA development was particularly sensitive to reduced Tbx1 dosage, 
4th PAA hypoplasia appearing already at 70% wild-type levels of mRNA. Outflow tract 
septation defects were observed at 20% and alignment defects at 15%. Therefore Tbx1 
dosage manipulations using hypomorphic alleles revealed that different tissues have different 
sensitivity to Tbx1 dosage. 
I found that Trp53 heterozygous deletion was partially effective in rescuing the cardiac 
outflow tract phenotype in hypomorphic mutants, and ineffective in null mutants. This 
differential response to Trp53 deletion can be interpreted in different ways. For example, it 
might be necessary to have a particular balance between dosage of Tbx1 and dosage of 
Trp53, therefore to have an effective rescue in a Tbx1 null background and to maintain this 
balance, I should completely delete Trp53. This hypothesis, however, does not explain well 
the apparent lack of rescue in the null, considering that a partial rescue can readily be 
detected In embryos with only -15% of the Tbx1 mRNA. Another possibility is that in the 
null, the anatomical structures or tissues sensitive to p53-dependent rescue are severely 
disrupted or even absent and thus a rescue cannot occur. This may be the case for the 
posterior pharyngeal arch artery system, which is absent in the null, but is unlikely to be the 
case for the OFT, which is formed in the null but not modified by Trp53 deletion. In contrast, 
Increased cell proliferation associated with Trp53 deletion may explain the improvement of 
the OFT phenotype observed In Tbx1 hypomorphic mutants, as reduced cell proliferation in 
the SHF is associated with OFT abnormalities (Vincent and Buckingham 2010; Xu, 
Morishlma et al. 2004; Prall, Menon et al. 2007). 
I propose that Gbx2 is a strong candidate gene, whose rescued expression in combined 
Tbx1 and Trp53 mutants could explain the rescue of the 4th PAA phenotype. Gbx2 has been 
studied mostly as a regulator of midbrain development (Joyner, Liu et aI., 2000). It has been 
reported that Gbx2 homozygous null embryos exhibit cerebellar defects and die soon after 
birth (Wassarman, Lewandoski et aI., 1997). Mutants pups were cyanotiC at birth, suggesting 
that neonatal lethality may be attributable to cardiovascular defects, in fact, approximately 
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39% of Gbx2 mutants exhibit cardiovascular defects that are not limited to the remodeling of 
the PAAs, but they also exhibit VSDs and OFT malformations (Byrd and Meyers, 2005). 
Gbx2 is not expressed in the SHF, therefore it cannot explain the partial rescue of the OFT 
phenotype, which is due to loss of Tbx1 in the mesoderm (Zhang, Huynh et al. 2006). 
Moreover, Gbx2 has been identified as a· downstream target of signal transducer and 
activator of transcription 3 (Stat3), a transcription factor that forms a homodimer upon 
induction by leukemia inhibitor factor (LlF) and subsequently translocates into the nucleus, 
where it regulates transcription of its downstream targets to maintain embryonic stem cell 
(ESC) identity. Gbx2, as a novel target of Stat3, seems to have a role in maintaining the 
undifferentiated state of mESC and in sustaining mESC self-renewal in the absence of LlF; 
and it functions also as a reprogramming factor, cooperating synergistically with Oct4, Sox2, 
Klf4 and c-Myc (Tai and Ylng, 2013). Therefore, It Is possible that Gbx2 has a role also in 
promoting proliferation and In Inhibiting differentiation. Because Gbx2 is not expressed in the 
SHF, its role in OFT development is indirect. Whether or not Tbx1-dependent expression of 
Gbx2 is critical to OFT development Is not clear. However, we cannot exclude that Trp53 
deletion improved the OFT phenotype by buffering the effects of the loss of Tbx1 on Gbx2 
regulation. 
In summary, I propose that p53 and Tbx1 co-reg u late , in a contrasting manner, a set 
of common target genes. Consequently, the reduced dosage of p53 enhances the 
transcriptional functions of Tbx1 on those targets. The evidence in support of this view is 
based upon our chromatin co-immunopreclpitation data, co-occupation and co-regulation of 
the Gbx2 gene. In addition, both Tbx1 and p53 interact with the same component of the SWI-
SNF chromatin remodeling complex Smarcd1/Baf60a (Chen, Fulcoli et al.; Oh, Sohn et al. 
2008), suggesting that the two transcription factors may interact with the same machinery at 
a chromatin level. It has also been shown that p53 Interacts with a component of the 
polycomb repressive complex 2 (Yang, Wang et al. 2013) and, by doing so it could add 
repressive marks (H3K27me3) on a set of targets, including some of the Tbx1 targets, thus 
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making them less likely to be activated by Tbx1. Our finding that p53 dosage affects 
negatively the enrichment of H3K27me3 at the genetic element occupied by Tbx1 and p53 
supports the hypothesis that reduced expression of p53 reduces repressive marks on the 
Gbx2 gene and thereby "facilitates" its regulation by Tbx1. This rescue mechanism requires 
the presence of the Tbx1 protein, thus explaining why p53 suppression has no effect on the 
null Tbx1 phenotype. A schematic representation of a proposed model by which Tbx1-p53 
regulate Gbx2 expression is shown in Fig. 29. 
Finally, my data suggest, for the first time, that p53 plays a role in the biology of 
cardiac progenitors. While the loss of Trp53 has no effect on cardiac development, it is 
known that p53 occupies a large set of developmentally critical genes, including genes 
involved in cardiac development (Akdemir, Jain et al. 2013). While its exact role on cardiac 
differentiation remains to be defined, I speculate that part of this role would be to keep genes 
involved in cardiac differentiation open for transcriptions (and/or suppress genes important to 
maintain the progenitor state) and thus facilitate the switch from progenitor state to 
differentiated state. 
In view of the complexities of p53 functions in the context of embryonic development and cell 
differentiation (Rivlin, Koifman et aI., 2014; Danilova, Sakamoto et aI., 2008; Armstrong, 
Kaufman et aI., 1995; Sah, Attardi et al., 1995), it is possible that Gbx2 is not the only player 
in phenotypic rescue. Nevertheless, our data about the Gbx2 gene illustrate an intriguing 
mechanism of interaction that might function also on other shared target genes yet to be 
identified. Therefore, further work is required to address my hypothesis. For example, it 
would be Interesting to carry out sequential ChiP assays followed by deep sequencing (re-
Chip-seq) to have a genome-wide analysis of co-occupied enhancers. Parallel gene 
expression analysis (RNA-seq) will identify neighboring target genes sensitive to Tbx1/Trp53 
dosage balance. Furthermore, genome-wide ChiP-seq assays in Tbx1-Trp53 combined 
mutants should provide gene features and chromatin prOfiling compared to the control 
mutants. Another experimental would test whether there is competition between the two 
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transcription factors in binding Baf60a. Indeed, the SWI-SNF-like subunit Baf60a binds p53 
and Tbx1 and is very important, if not essential, for the function of both transcription factors 
(Chen , Fulcoli et aI. , 2012 ; Oh, Sohn et aI. , 2008). 
Last but not least, my data provide a proof of concept that the Tbx1 mutant 
phenotype can be significantly ameliorated using pharmacologica l approaches , thus 
encourag ing further studies into the functional mechanisms and interactions of Tbx1 with the 
aim of identifying potential drug targets. 
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Figure 29: Schematic model of Gbx2 regulation. My data suggest that when there is a 
balance between Tbx1 and p53, Tbx1 directly regulate Gbx2 causing a massive expression 
of the gene (A). When Tbx1 is reduced, there is an unbalance between the two transcription 
factors causing a reduction of Gbx2 expression (B). The restoration of the balance between 
Tbx1 and p53 results in a rescue of the Gbx2 expression, due to the reduction of the 
repressive mark H3K27me3 (C). 
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